JP2017527588A - P2x7調節n−アシル−トリアゾロピラジン - Google Patents
P2x7調節n−アシル−トリアゾロピラジン Download PDFInfo
- Publication number
- JP2017527588A JP2017527588A JP2017513686A JP2017513686A JP2017527588A JP 2017527588 A JP2017527588 A JP 2017527588A JP 2017513686 A JP2017513686 A JP 2017513686A JP 2017513686 A JP2017513686 A JP 2017513686A JP 2017527588 A JP2017527588 A JP 2017527588A
- Authority
- JP
- Japan
- Prior art keywords
- triazolo
- dihydro
- methanone
- phenyl
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title claims abstract description 40
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title claims abstract description 40
- 150000001875 compounds Chemical class 0.000 claims abstract description 291
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 93
- 201000010099 disease Diseases 0.000 claims abstract description 67
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 24
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 19
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims abstract description 13
- 230000003959 neuroinflammation Effects 0.000 claims abstract description 13
- 230000002503 metabolic effect Effects 0.000 claims abstract description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 9
- 230000001363 autoimmune Effects 0.000 claims abstract description 9
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 9
- 210000005095 gastrointestinal system Anatomy 0.000 claims abstract 2
- -1 2,3-dichlorophenyl Chemical group 0.000 claims description 112
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 208000002193 Pain Diseases 0.000 claims description 27
- 208000035475 disorder Diseases 0.000 claims description 22
- 208000006673 asthma Diseases 0.000 claims description 20
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 15
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 14
- 208000019022 Mood disease Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 208000024714 major depressive disease Diseases 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 208000004296 neuralgia Diseases 0.000 claims description 9
- 208000021722 neuropathic pain Diseases 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 230000006870 function Effects 0.000 claims description 8
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 8
- 210000001635 urinary tract Anatomy 0.000 claims description 8
- 208000000094 Chronic Pain Diseases 0.000 claims description 7
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 7
- 208000025609 Urogenital disease Diseases 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 208000005298 acute pain Diseases 0.000 claims description 7
- 230000002269 spontaneous effect Effects 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 206010003805 Autism Diseases 0.000 claims description 5
- 208000020706 Autistic disease Diseases 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 5
- 201000006474 Brain Ischemia Diseases 0.000 claims description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
- 208000024699 Chagas disease Diseases 0.000 claims description 5
- 241000606161 Chlamydia Species 0.000 claims description 5
- 208000020401 Depressive disease Diseases 0.000 claims description 5
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 5
- 206010065390 Inflammatory pain Diseases 0.000 claims description 5
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
- 206010040047 Sepsis Diseases 0.000 claims description 5
- 206010040070 Septic Shock Diseases 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 201000010105 allergic rhinitis Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 5
- 230000019771 cognition Effects 0.000 claims description 5
- 210000003499 exocrine gland Anatomy 0.000 claims description 5
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 230000036303 septic shock Effects 0.000 claims description 5
- 208000019116 sleep disease Diseases 0.000 claims description 5
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- 201000008827 tuberculosis Diseases 0.000 claims description 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- 208000008035 Back Pain Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- GXUNQUAKEGNJER-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1C)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1C)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 GXUNQUAKEGNJER-UHFFFAOYSA-N 0.000 claims description 4
- LEKYBEUSNCUHQO-NSHDSACASA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC=C(C=C1)F LEKYBEUSNCUHQO-NSHDSACASA-N 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 206010021639 Incontinence Diseases 0.000 claims description 4
- 208000008930 Low Back Pain Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 4
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims description 4
- 208000007536 Thrombosis Diseases 0.000 claims description 4
- 208000004608 Ureteral Obstruction Diseases 0.000 claims description 4
- 230000010085 airway hyperresponsiveness Effects 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 208000002865 osteopetrosis Diseases 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- SQXLSOCWRJERMK-VIFPVBQESA-N ClC1=C(C=CC(=C1Cl)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C(=CC=C1)F)F Chemical compound ClC1=C(C=CC(=C1Cl)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C(=CC=C1)F)F SQXLSOCWRJERMK-VIFPVBQESA-N 0.000 claims description 3
- OIGGOJWMKHIZKZ-JTQLQIEISA-N ClC1=C(C=CC(=C1Cl)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C=CC=C1)F Chemical compound ClC1=C(C=CC(=C1Cl)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C=CC=C1)F OIGGOJWMKHIZKZ-JTQLQIEISA-N 0.000 claims description 3
- URXJAPUKUWITQZ-VIFPVBQESA-N ClC1=C(C=CC(=C1Cl)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=C(C=C1)F)F Chemical compound ClC1=C(C=CC(=C1Cl)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=C(C=C1)F)F URXJAPUKUWITQZ-VIFPVBQESA-N 0.000 claims description 3
- YNMFBSOEGDHKTE-JTQLQIEISA-N ClC1=C(C=CC(=C1Cl)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=CC=C1)F Chemical compound ClC1=C(C=CC(=C1Cl)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=CC=C1)F YNMFBSOEGDHKTE-JTQLQIEISA-N 0.000 claims description 3
- DIKZWBAANZCKMW-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C)C1=CC=CC=C1 DIKZWBAANZCKMW-UHFFFAOYSA-N 0.000 claims description 3
- LFIVNQALZJXDAJ-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=CC=C(C=C1)F)C Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=CC=C(C=C1)F)C LFIVNQALZJXDAJ-UHFFFAOYSA-N 0.000 claims description 3
- CIHDMWDFPHPZMN-JTQLQIEISA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C(=CC=C1)F)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C(=CC=C1)F)F CIHDMWDFPHPZMN-JTQLQIEISA-N 0.000 claims description 3
- WHHVFHYDJDVVPL-JTQLQIEISA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C=C(C=C1)F)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C=C(C=C1)F)F WHHVFHYDJDVVPL-JTQLQIEISA-N 0.000 claims description 3
- BAMOHIFAUIEHFQ-NSHDSACASA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C=CC=C1)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C=CC=C1)F BAMOHIFAUIEHFQ-NSHDSACASA-N 0.000 claims description 3
- ORGBWFLQGGFIRG-VIFPVBQESA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=C(C(=C1)F)F)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=C(C(=C1)F)F)F ORGBWFLQGGFIRG-VIFPVBQESA-N 0.000 claims description 3
- MTNYNSBCZIDBQS-JTQLQIEISA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=C(C=C1)C(F)(F)F)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=C(C=C1)C(F)(F)F)F MTNYNSBCZIDBQS-JTQLQIEISA-N 0.000 claims description 3
- PQJLQSVXKUXUHM-JTQLQIEISA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=C(C=C1)F)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=C(C=C1)F)F PQJLQSVXKUXUHM-JTQLQIEISA-N 0.000 claims description 3
- IFHHOCFUGYKLED-NSHDSACASA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=CC=C1)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=CC=C1)F IFHHOCFUGYKLED-NSHDSACASA-N 0.000 claims description 3
- JRWVKSGGYCQTMM-NSHDSACASA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC=C(C=C1)C(F)(F)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC=C(C=C1)C(F)(F)F JRWVKSGGYCQTMM-NSHDSACASA-N 0.000 claims description 3
- TWXUMRZAJBDOAU-OAHLLOKOSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)F)C1=CC=CC=C1 TWXUMRZAJBDOAU-OAHLLOKOSA-N 0.000 claims description 3
- QTGBZZVRWIHLMR-JTQLQIEISA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C(=CC=C1)F)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C(=CC=C1)F)F QTGBZZVRWIHLMR-JTQLQIEISA-N 0.000 claims description 3
- DTDZAOKTYGRZQU-NSHDSACASA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C=CC=C1)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C=CC=C1)F DTDZAOKTYGRZQU-NSHDSACASA-N 0.000 claims description 3
- YIANRDCMONYMOB-NSHDSACASA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=CC=C1)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=CC=C1)F YIANRDCMONYMOB-NSHDSACASA-N 0.000 claims description 3
- YPTLIGPRZNCUDE-VIFPVBQESA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=C(C=N1)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=C(C=N1)F YPTLIGPRZNCUDE-VIFPVBQESA-N 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 3
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 3
- MULCYNKNDJVWBS-VJNLCDJLSA-N (2,3-dichlorophenyl)-[(6S)-3-(4-(111C)methoxypyridin-2-yl)-6-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=CC(=C1)O[11CH3] MULCYNKNDJVWBS-VJNLCDJLSA-N 0.000 claims description 2
- BACUOQUEHLTBIV-APCSIUFUSA-N (2,3-dichlorophenyl)-[(6S)-3-(4-(18F)fluoranylpyridin-2-yl)-6-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=CC(=C1)[18F] BACUOQUEHLTBIV-APCSIUFUSA-N 0.000 claims description 2
- KUNCMOAFNYLOSC-UHFFFAOYSA-N 2-chloro-3-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC(C=O)=C1Cl KUNCMOAFNYLOSC-UHFFFAOYSA-N 0.000 claims description 2
- HSXVJLICURLLBY-GOSISDBHSA-N C(C)(C)(C)C1=NN=C2N1CCN([C@@H]2C1=CC=CC=C1)C(=O)C1=C(C(=CC=C1)C(F)(F)F)Cl Chemical compound C(C)(C)(C)C1=NN=C2N1CCN([C@@H]2C1=CC=CC=C1)C(=O)C1=C(C(=CC=C1)C(F)(F)F)Cl HSXVJLICURLLBY-GOSISDBHSA-N 0.000 claims description 2
- HSXVJLICURLLBY-SFHVURJKSA-N C(C)(C)(C)C1=NN=C2N1CCN([C@H]2C1=CC=CC=C1)C(=O)C1=C(C(=CC=C1)C(F)(F)F)Cl Chemical compound C(C)(C)(C)C1=NN=C2N1CCN([C@H]2C1=CC=CC=C1)C(=O)C1=C(C(=CC=C1)C(F)(F)F)Cl HSXVJLICURLLBY-SFHVURJKSA-N 0.000 claims description 2
- VPYMQPNTICLKCI-UHFFFAOYSA-N C1(CC1)C1=NN=C2N1CCN(C2C)C(=O)C1=C(C(=C(C=C1)F)Cl)Cl Chemical compound C1(CC1)C1=NN=C2N1CCN(C2C)C(=O)C1=C(C(=C(C=C1)F)Cl)Cl VPYMQPNTICLKCI-UHFFFAOYSA-N 0.000 claims description 2
- HHGVUKLWJHPGRE-UHFFFAOYSA-N C1(CC1)C1=NN=C2N1CCN(C2C)C(=O)C1=C(C(=CC=C1)Cl)Cl Chemical compound C1(CC1)C1=NN=C2N1CCN(C2C)C(=O)C1=C(C(=CC=C1)Cl)Cl HHGVUKLWJHPGRE-UHFFFAOYSA-N 0.000 claims description 2
- YAOWZRGEDLORPB-UHFFFAOYSA-N C1(CCCCC1)C1=NN=C2N1CCN(C2C)C(=O)C1=C(C(=C(C=C1)F)Cl)Cl Chemical compound C1(CCCCC1)C1=NN=C2N1CCN(C2C)C(=O)C1=C(C(=C(C=C1)F)Cl)Cl YAOWZRGEDLORPB-UHFFFAOYSA-N 0.000 claims description 2
- WKKJPQOPEWVRRT-UHFFFAOYSA-N C1(CCCCC1)C1=NN=C2N1CCN(C2C)C(=O)C1=C(C(=CC=C1)Cl)Cl Chemical compound C1(CCCCC1)C1=NN=C2N1CCN(C2C)C(=O)C1=C(C(=CC=C1)Cl)Cl WKKJPQOPEWVRRT-UHFFFAOYSA-N 0.000 claims description 2
- PYWQKUAVSCZRTP-MRXNPFEDSA-N CC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound CC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 PYWQKUAVSCZRTP-MRXNPFEDSA-N 0.000 claims description 2
- PYWQKUAVSCZRTP-INIZCTEOSA-N CC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound CC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 PYWQKUAVSCZRTP-INIZCTEOSA-N 0.000 claims description 2
- ZOXWUDZAOKBWPG-OAHLLOKOSA-N ClC1=C(C=CC(=C1)Cl)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC(=C1)Cl)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 ZOXWUDZAOKBWPG-OAHLLOKOSA-N 0.000 claims description 2
- ZOXWUDZAOKBWPG-HNNXBMFYSA-N ClC1=C(C=CC(=C1)Cl)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC(=C1)Cl)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 ZOXWUDZAOKBWPG-HNNXBMFYSA-N 0.000 claims description 2
- PFLNEVHZZNMUSA-UHFFFAOYSA-N ClC1=C(C=CC(=C1)F)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC(=C1)F)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=CC=C1 PFLNEVHZZNMUSA-UHFFFAOYSA-N 0.000 claims description 2
- YTJLHYGTIVNAFW-OAHLLOKOSA-N ClC1=C(C=CC(=C1)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC(=C1)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 YTJLHYGTIVNAFW-OAHLLOKOSA-N 0.000 claims description 2
- YTJLHYGTIVNAFW-HNNXBMFYSA-N ClC1=C(C=CC(=C1)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC(=C1)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 YTJLHYGTIVNAFW-HNNXBMFYSA-N 0.000 claims description 2
- WXESHKLAQUXJQB-VIFPVBQESA-N ClC1=C(C=CC(=C1Cl)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C=C(C=C1)F)F Chemical compound ClC1=C(C=CC(=C1Cl)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C=C(C=C1)F)F WXESHKLAQUXJQB-VIFPVBQESA-N 0.000 claims description 2
- SYZMITDDJPHNMD-UHFFFAOYSA-N ClC1=C(C=CC=C1)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=CC=C1 SYZMITDDJPHNMD-UHFFFAOYSA-N 0.000 claims description 2
- DDLVLLHHDGWMBY-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C(C)O)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C(C)O)C1=CC=CC=C1 DDLVLLHHDGWMBY-UHFFFAOYSA-N 0.000 claims description 2
- OJHQUOGNBLXVTC-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 OJHQUOGNBLXVTC-UHFFFAOYSA-N 0.000 claims description 2
- OJKQXEKORIHWTD-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C(F)(F)F)C=1C=NC=CC=1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C(F)(F)F)C=1C=NC=CC=1 OJKQXEKORIHWTD-UHFFFAOYSA-N 0.000 claims description 2
- DGCIQEFIEGXSGC-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C)C1=CC=C(C=C1)F DGCIQEFIEGXSGC-UHFFFAOYSA-N 0.000 claims description 2
- PJSMHLSMTBVIQD-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=CC=C(C=C1)C(F)(F)F)C Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=CC=C(C=C1)C(F)(F)F)C PJSMHLSMTBVIQD-UHFFFAOYSA-N 0.000 claims description 2
- MSLGOANNDWOOQP-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=CC=C(C=C1)Cl)C Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=CC=C(C=C1)Cl)C MSLGOANNDWOOQP-UHFFFAOYSA-N 0.000 claims description 2
- FZZBUSFLTZARKM-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1CC1)C Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1CC1)C FZZBUSFLTZARKM-UHFFFAOYSA-N 0.000 claims description 2
- YGLDZWHUAGAZTE-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C(C1)C)C(=NN=2)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C(C1)C)C(=NN=2)C1=CC=C(C=C1)F YGLDZWHUAGAZTE-UHFFFAOYSA-N 0.000 claims description 2
- UJTOQBQDAYTWPS-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=C(C=C1)F UJTOQBQDAYTWPS-UHFFFAOYSA-N 0.000 claims description 2
- UJTOQBQDAYTWPS-NSHDSACASA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC=C(C=C1)F UJTOQBQDAYTWPS-NSHDSACASA-N 0.000 claims description 2
- ZBWWENBLBXGTGG-LBPRGKRZSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC=CC=C1 ZBWWENBLBXGTGG-LBPRGKRZSA-N 0.000 claims description 2
- BKKDEABNTAGZKU-JTQLQIEISA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=C(C=C1)F BKKDEABNTAGZKU-JTQLQIEISA-N 0.000 claims description 2
- VRFGJUBALKWLKX-NSHDSACASA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=C(C=C1)OC Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=C(C=C1)OC VRFGJUBALKWLKX-NSHDSACASA-N 0.000 claims description 2
- ZBWWENBLBXGTGG-GFCCVEGCSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@H]1C)C(=NN=2)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@H]1C)C(=NN=2)C1=CC=CC=C1 ZBWWENBLBXGTGG-GFCCVEGCSA-N 0.000 claims description 2
- ZJZAAKTXWLBDMW-GOSISDBHSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(C)C)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(C)C)C1=CC=CC=C1 ZJZAAKTXWLBDMW-GOSISDBHSA-N 0.000 claims description 2
- OJHQUOGNBLXVTC-OAHLLOKOSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 OJHQUOGNBLXVTC-OAHLLOKOSA-N 0.000 claims description 2
- DGCIQEFIEGXSGC-QGZVFWFLSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C)C1=CC=C(C=C1)F DGCIQEFIEGXSGC-QGZVFWFLSA-N 0.000 claims description 2
- DIKZWBAANZCKMW-QGZVFWFLSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C)C1=CC=CC=C1 DIKZWBAANZCKMW-QGZVFWFLSA-N 0.000 claims description 2
- ROFJGLWXJONZPU-GOSISDBHSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C1CC1)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C1CC1)C1=CC=CC=C1 ROFJGLWXJONZPU-GOSISDBHSA-N 0.000 claims description 2
- UEWFFCDVOITNDG-LJQANCHMSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C1CCC1)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C1CCC1)C1=CC=CC=C1 UEWFFCDVOITNDG-LJQANCHMSA-N 0.000 claims description 2
- PLUYODJABXFQED-LJQANCHMSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C=1OC=CC=1)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C=1OC=CC=1)C1=CC=CC=C1 PLUYODJABXFQED-LJQANCHMSA-N 0.000 claims description 2
- ACIARRDYJJFASA-GOSISDBHSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)CC)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)CC)C1=CC=CC=C1 ACIARRDYJJFASA-GOSISDBHSA-N 0.000 claims description 2
- ZJZAAKTXWLBDMW-SFHVURJKSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(C)C)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(C)C)C1=CC=CC=C1 ZJZAAKTXWLBDMW-SFHVURJKSA-N 0.000 claims description 2
- OJHQUOGNBLXVTC-HNNXBMFYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 OJHQUOGNBLXVTC-HNNXBMFYSA-N 0.000 claims description 2
- TWXUMRZAJBDOAU-HNNXBMFYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)F)C1=CC=CC=C1 TWXUMRZAJBDOAU-HNNXBMFYSA-N 0.000 claims description 2
- DGCIQEFIEGXSGC-KRWDZBQOSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C)C1=CC=C(C=C1)F DGCIQEFIEGXSGC-KRWDZBQOSA-N 0.000 claims description 2
- DIKZWBAANZCKMW-KRWDZBQOSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C)C1=CC=CC=C1 DIKZWBAANZCKMW-KRWDZBQOSA-N 0.000 claims description 2
- ROFJGLWXJONZPU-SFHVURJKSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C1CC1)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C1CC1)C1=CC=CC=C1 ROFJGLWXJONZPU-SFHVURJKSA-N 0.000 claims description 2
- UEWFFCDVOITNDG-IBGZPJMESA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C1CCC1)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C1CCC1)C1=CC=CC=C1 UEWFFCDVOITNDG-IBGZPJMESA-N 0.000 claims description 2
- ACIARRDYJJFASA-SFHVURJKSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)CC)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)CC)C1=CC=CC=C1 ACIARRDYJJFASA-SFHVURJKSA-N 0.000 claims description 2
- ZGCWKWGVCHAZLU-UHFFFAOYSA-N ClC1=C(C=CC=C1Cl)C(=O)N1C(C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1C(C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 ZGCWKWGVCHAZLU-UHFFFAOYSA-N 0.000 claims description 2
- HZFBDSBFUYCNMB-UHFFFAOYSA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C(C1)C)C(=NN=2)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C(C1)C)C(=NN=2)C1=CC=C(C=C1)F HZFBDSBFUYCNMB-UHFFFAOYSA-N 0.000 claims description 2
- YLSVSONEZDHLCV-UHFFFAOYSA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C(C1)C)C(=NN=2)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C(C1)C)C(=NN=2)C1=CC=CC=C1 YLSVSONEZDHLCV-UHFFFAOYSA-N 0.000 claims description 2
- LEKYBEUSNCUHQO-UHFFFAOYSA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=C(C=C1)F LEKYBEUSNCUHQO-UHFFFAOYSA-N 0.000 claims description 2
- HJXDJVUZQAGWAO-UHFFFAOYSA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=CC=C1 HJXDJVUZQAGWAO-UHFFFAOYSA-N 0.000 claims description 2
- WOOQFRKREASKNB-JTQLQIEISA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C=C(C=C1)F)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=C(C=C(C=C1)F)F WOOQFRKREASKNB-JTQLQIEISA-N 0.000 claims description 2
- SERLXQDDSQEJFM-JTQLQIEISA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=C(C=C1)F)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=C(C=C1)F)F SERLXQDDSQEJFM-JTQLQIEISA-N 0.000 claims description 2
- HJXDJVUZQAGWAO-LBPRGKRZSA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC=CC=C1 HJXDJVUZQAGWAO-LBPRGKRZSA-N 0.000 claims description 2
- IITDXWDZXDVZRA-JTQLQIEISA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC(=CC=C1)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC(=CC=C1)F IITDXWDZXDVZRA-JTQLQIEISA-N 0.000 claims description 2
- AACREYRHBBEZTH-JTQLQIEISA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=C(C=C1)F AACREYRHBBEZTH-JTQLQIEISA-N 0.000 claims description 2
- YYNSGVLPEOXSPO-JTQLQIEISA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=CC(=C1)O Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=CC(=C1)O YYNSGVLPEOXSPO-JTQLQIEISA-N 0.000 claims description 2
- MULCYNKNDJVWBS-NSHDSACASA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=CC(=C1)OC Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=CC(=C1)OC MULCYNKNDJVWBS-NSHDSACASA-N 0.000 claims description 2
- RSIPEUHWMRBWAI-JTQLQIEISA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=CN=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=CN=C1 RSIPEUHWMRBWAI-JTQLQIEISA-N 0.000 claims description 2
- LEKYBEUSNCUHQO-LLVKDONJSA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@H]1C)C(=NN=2)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@H]1C)C(=NN=2)C1=CC=C(C=C1)F LEKYBEUSNCUHQO-LLVKDONJSA-N 0.000 claims description 2
- HJXDJVUZQAGWAO-GFCCVEGCSA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@H]1C)C(=NN=2)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@H]1C)C(=NN=2)C1=CC=CC=C1 HJXDJVUZQAGWAO-GFCCVEGCSA-N 0.000 claims description 2
- ZGCWKWGVCHAZLU-OAHLLOKOSA-N ClC1=C(C=CC=C1Cl)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 ZGCWKWGVCHAZLU-OAHLLOKOSA-N 0.000 claims description 2
- YWDSXJPUMIRHHC-QGZVFWFLSA-N ClC1=C(C=CC=C1Cl)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C)C1=CC=C(C=C1)F YWDSXJPUMIRHHC-QGZVFWFLSA-N 0.000 claims description 2
- ZGCWKWGVCHAZLU-HNNXBMFYSA-N ClC1=C(C=CC=C1Cl)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 ZGCWKWGVCHAZLU-HNNXBMFYSA-N 0.000 claims description 2
- YWDSXJPUMIRHHC-KRWDZBQOSA-N ClC1=C(C=CC=C1Cl)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C)C1=CC=C(C=C1)F YWDSXJPUMIRHHC-KRWDZBQOSA-N 0.000 claims description 2
- VDXCOPNSTRALDU-UHFFFAOYSA-N ClC1=NC=CC(=C1Cl)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=CC=C1 Chemical compound ClC1=NC=CC(=C1Cl)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=CC=C1 VDXCOPNSTRALDU-UHFFFAOYSA-N 0.000 claims description 2
- VISHDOGBTBRDCI-OAHLLOKOSA-N FC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound FC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 VISHDOGBTBRDCI-OAHLLOKOSA-N 0.000 claims description 2
- VISHDOGBTBRDCI-HNNXBMFYSA-N FC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound FC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 VISHDOGBTBRDCI-HNNXBMFYSA-N 0.000 claims description 2
- CMPWLGLFBPCHPX-GOSISDBHSA-N FC1=CC=C(C=C1)[C@@H]1C=2N(CCN1C(=O)C1=C(C(=CC=C1)C(F)(F)F)C)C(=NN=2)C Chemical compound FC1=CC=C(C=C1)[C@@H]1C=2N(CCN1C(=O)C1=C(C(=CC=C1)C(F)(F)F)C)C(=NN=2)C CMPWLGLFBPCHPX-GOSISDBHSA-N 0.000 claims description 2
- HQPUMQBXULIPNN-UHFFFAOYSA-N FC=1C(=C(C=CC=1F)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=CC=C1)C Chemical compound FC=1C(=C(C=CC=1F)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=CC=C1)C HQPUMQBXULIPNN-UHFFFAOYSA-N 0.000 claims description 2
- ZYTITAJYGJXDLO-UHFFFAOYSA-N N1N=CC=C1C1C=2N(CCN1C(=O)C1=C(C(=CC=C1)C(F)(F)F)Cl)C(=NN=2)C(F)(F)F Chemical compound N1N=CC=C1C1C=2N(CCN1C(=O)C1=C(C(=CC=C1)C(F)(F)F)Cl)C(=NN=2)C(F)(F)F ZYTITAJYGJXDLO-UHFFFAOYSA-N 0.000 claims description 2
- ZHWCWBIABWODSU-JTQLQIEISA-N [2-chloro-3-(trifluoromethyl)phenyl]-[(6S)-3-(5-methoxypyrimidin-2-yl)-6-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=C(C=N1)OC ZHWCWBIABWODSU-JTQLQIEISA-N 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 34
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- CUQHTBQRXZCFTC-UHFFFAOYSA-N 2-methyl-3-(trifluoromethyl)benzaldehyde Chemical compound CC1=C(C=O)C=CC=C1C(F)(F)F CUQHTBQRXZCFTC-UHFFFAOYSA-N 0.000 claims 1
- OISNJHWDFIUJGA-OAHLLOKOSA-N ClC1=C(C=CC(=C1Cl)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC(=C1Cl)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 OISNJHWDFIUJGA-OAHLLOKOSA-N 0.000 claims 1
- OISNJHWDFIUJGA-HNNXBMFYSA-N ClC1=C(C=CC(=C1Cl)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC(=C1Cl)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)(F)F)C1=CC=CC=C1 OISNJHWDFIUJGA-HNNXBMFYSA-N 0.000 claims 1
- SIZSYSCZGKCDPI-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=NC=CC=C1)C Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=NC=CC=C1)C SIZSYSCZGKCDPI-UHFFFAOYSA-N 0.000 claims 1
- ZAJVOXZSUBHRRY-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=NC=CN=C1)C Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=NC=CN=C1)C ZAJVOXZSUBHRRY-UHFFFAOYSA-N 0.000 claims 1
- LZWRWGLXFWYQSP-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1CCCCC1)C Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1CCCCC1)C LZWRWGLXFWYQSP-UHFFFAOYSA-N 0.000 claims 1
- ZBWWENBLBXGTGG-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(CC1C)C(=NN=2)C1=CC=CC=C1 ZBWWENBLBXGTGG-UHFFFAOYSA-N 0.000 claims 1
- QJDRIPNRVGOLBB-NSHDSACASA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC=C(C=C1)C(F)(F)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC=C(C=C1)C(F)(F)F QJDRIPNRVGOLBB-NSHDSACASA-N 0.000 claims 1
- NSZZEUGLOYHMNJ-NSHDSACASA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=C(C=C1)OC Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=C(C=C1)OC NSZZEUGLOYHMNJ-NSHDSACASA-N 0.000 claims 1
- BWTYBBRWSXSDAS-NSHDSACASA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=CC=C1 BWTYBBRWSXSDAS-NSHDSACASA-N 0.000 claims 1
- QBVDDRFEZRIHRZ-OAHLLOKOSA-N ClC1=C(C=CC=C1Cl)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C(F)F)C1=CC=CC=C1 QBVDDRFEZRIHRZ-OAHLLOKOSA-N 0.000 claims 1
- USAGXNSIENSYBF-MRXNPFEDSA-N ClC1=C(C=CC=C1Cl)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C)C1=NC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C)C1=NC=CC=C1 USAGXNSIENSYBF-MRXNPFEDSA-N 0.000 claims 1
- LKRYOMVAVRZUMD-LLVKDONJSA-N ClC1=C(C=CC=C1Cl)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C1=NC=CC=C1)C Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C1=NC=CC=C1)C LKRYOMVAVRZUMD-LLVKDONJSA-N 0.000 claims 1
- QBVDDRFEZRIHRZ-HNNXBMFYSA-N ClC1=C(C=CC=C1Cl)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C(F)F)C1=CC=CC=C1 QBVDDRFEZRIHRZ-HNNXBMFYSA-N 0.000 claims 1
- USAGXNSIENSYBF-INIZCTEOSA-N ClC1=C(C=CC=C1Cl)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C)C1=NC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C)C1=NC=CC=C1 USAGXNSIENSYBF-INIZCTEOSA-N 0.000 claims 1
- LKRYOMVAVRZUMD-NSHDSACASA-N ClC1=C(C=CC=C1Cl)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C1=NC=CC=C1)C Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C1=NC=CC=C1)C LKRYOMVAVRZUMD-NSHDSACASA-N 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- BEOVYTUZTURCQK-UHFFFAOYSA-N FC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=NC=CC=C1)C Chemical compound FC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=NC=CC=C1)C BEOVYTUZTURCQK-UHFFFAOYSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 12
- 230000001703 neuroimmune Effects 0.000 abstract description 10
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 7
- 230000002496 gastric effect Effects 0.000 abstract description 7
- 210000002229 urogenital system Anatomy 0.000 abstract 1
- 239000000047 product Substances 0.000 description 174
- 238000000132 electrospray ionisation Methods 0.000 description 140
- 238000001819 mass spectrum Methods 0.000 description 140
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 111
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 105
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- 238000005481 NMR spectroscopy Methods 0.000 description 78
- 239000000460 chlorine Substances 0.000 description 78
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 73
- 239000011541 reaction mixture Substances 0.000 description 71
- 239000000243 solution Substances 0.000 description 62
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 58
- 239000012071 phase Substances 0.000 description 58
- 239000000203 mixture Substances 0.000 description 52
- 229910002091 carbon monoxide Inorganic materials 0.000 description 50
- 238000005160 1H NMR spectroscopy Methods 0.000 description 49
- 230000005526 G1 to G0 transition Effects 0.000 description 48
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 46
- 238000006243 chemical reaction Methods 0.000 description 44
- 230000002829 reductive effect Effects 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 239000002904 solvent Substances 0.000 description 37
- PKEMXTIVOBWBNO-UHFFFAOYSA-N 2-chloro-3-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC(C(Cl)=O)=C1Cl PKEMXTIVOBWBNO-UHFFFAOYSA-N 0.000 description 33
- 235000019439 ethyl acetate Nutrition 0.000 description 32
- 125000005843 halogen group Chemical group 0.000 description 32
- 101100441092 Danio rerio crlf3 gene Proteins 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 239000012044 organic layer Substances 0.000 description 28
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 28
- YBONBWJSFMTXLE-UHFFFAOYSA-N 2,3-dichlorobenzoyl chloride Chemical group ClC(=O)C1=CC=CC(Cl)=C1Cl YBONBWJSFMTXLE-UHFFFAOYSA-N 0.000 description 27
- 239000000651 prodrug Substances 0.000 description 27
- 229940002612 prodrug Drugs 0.000 description 27
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 238000004128 high performance liquid chromatography Methods 0.000 description 25
- GKBDXTNCBPZMFX-UHFFFAOYSA-N 4-(trifluoromethyl)benzohydrazide Chemical compound NNC(=O)C1=CC=C(C(F)(F)F)C=C1 GKBDXTNCBPZMFX-UHFFFAOYSA-N 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000000700 radioactive tracer Substances 0.000 description 21
- 239000007787 solid Substances 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
- 239000003643 water by type Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- IYXUFOCLMOXQSL-UHFFFAOYSA-N (2,2-difluoroacetyl) 2,2-difluoroacetate Chemical compound FC(F)C(=O)OC(=O)C(F)F IYXUFOCLMOXQSL-UHFFFAOYSA-N 0.000 description 15
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 229910004298 SiO 2 Inorganic materials 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000002207 metabolite Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 10
- UIVXXFYJRYVRKJ-UHFFFAOYSA-N 4-fluorobenzohydrazide Chemical compound NNC(=O)C1=CC=C(F)C=C1 UIVXXFYJRYVRKJ-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- KQGGDOBNHDZQNW-ZETCQYMHSA-N tert-butyl (2s)-2-methyl-5-sulfanylidenepiperazine-1-carboxylate Chemical compound C[C@H]1CNC(=S)CN1C(=O)OC(C)(C)C KQGGDOBNHDZQNW-ZETCQYMHSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- 241000894007 species Species 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- JFYKIEHOOZWARC-UHFFFAOYSA-N cyclopropanecarbohydrazide Chemical compound NNC(=O)C1CC1 JFYKIEHOOZWARC-UHFFFAOYSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000002287 radioligand Substances 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000000825 ultraviolet detection Methods 0.000 description 5
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical group ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 description 4
- DGEIQIPWWVMHAG-UHFFFAOYSA-N 8-phenyl-3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine-7-carbaldehyde Chemical compound C1(=CC=CC=C1)C1C=2N(CCN1C=O)C(=NN=2)C(F)(F)F DGEIQIPWWVMHAG-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 101001098238 Rattus norvegicus P2X purinoceptor 7 Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical group 0.000 description 4
- 239000001307 helium Substances 0.000 description 4
- 229910052734 helium Inorganic materials 0.000 description 4
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000003359 percent control normalization Methods 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000002603 single-photon emission computed tomography Methods 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000008279 sol Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- NYBJRGJELSODLU-ZETCQYMHSA-N tert-butyl (2s)-2-methyl-5-oxopiperazine-1-carboxylate Chemical compound C[C@H]1CNC(=O)CN1C(=O)OC(C)(C)C NYBJRGJELSODLU-ZETCQYMHSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- YRZZTHXOAMZZJG-UHFFFAOYSA-N (3-phenylpyrazin-2-yl)hydrazine Chemical compound NNC1=NC=CN=C1C1=CC=CC=C1 YRZZTHXOAMZZJG-UHFFFAOYSA-N 0.000 description 3
- VXJFZRUFEGHQQC-UHFFFAOYSA-N 1,3-oxazole-2-carbohydrazide Chemical compound NNC(=O)C1=NC=CO1 VXJFZRUFEGHQQC-UHFFFAOYSA-N 0.000 description 3
- LUWUTTHZUPOFCC-UHFFFAOYSA-N 2,3-dichloro-4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C(Cl)=C1Cl LUWUTTHZUPOFCC-UHFFFAOYSA-N 0.000 description 3
- QAOJBHRZQQDFHA-UHFFFAOYSA-N 2,3-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1Cl QAOJBHRZQQDFHA-UHFFFAOYSA-N 0.000 description 3
- OTAQPODTRVCAKB-UHFFFAOYSA-N 2,3-difluorobenzohydrazide Chemical group NNC(=O)C1=CC=CC(F)=C1F OTAQPODTRVCAKB-UHFFFAOYSA-N 0.000 description 3
- FGBCAURJSKHDGC-UHFFFAOYSA-N 2,4-difluorobenzohydrazide Chemical compound NNC(=O)C1=CC=C(F)C=C1F FGBCAURJSKHDGC-UHFFFAOYSA-N 0.000 description 3
- AXOAWWUSRZCGKS-UHFFFAOYSA-N 2-chloro-3-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1Cl AXOAWWUSRZCGKS-UHFFFAOYSA-N 0.000 description 3
- CAPLTXKTKMPKED-UHFFFAOYSA-N 2-chloro-3-phenylpyrazine Chemical compound ClC1=NC=CN=C1C1=CC=CC=C1 CAPLTXKTKMPKED-UHFFFAOYSA-N 0.000 description 3
- YJCCKQQVXNNAAR-UHFFFAOYSA-N 2-fluorobenzohydrazide Chemical group NNC(=O)C1=CC=CC=C1F YJCCKQQVXNNAAR-UHFFFAOYSA-N 0.000 description 3
- AWJJLYZBWRIBCZ-UGTJMOTHSA-N 3'-O-(4-Benzoyl)benzoyl ATP Chemical compound O([C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)N1C=2N=CN=C(C=2N=C1)N)C(=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 AWJJLYZBWRIBCZ-UGTJMOTHSA-N 0.000 description 3
- ILZMPXWYANDHDC-UHFFFAOYSA-N 3,4-difluorobenzohydrazide Chemical compound NNC(=O)C1=CC=C(F)C(F)=C1 ILZMPXWYANDHDC-UHFFFAOYSA-N 0.000 description 3
- HXGVVUGUPVEPNP-UHFFFAOYSA-N 3-(difluoromethyl)-8-phenyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine Chemical compound N1CCN2C(C(F)F)=NN=C2C1C1=CC=CC=C1 HXGVVUGUPVEPNP-UHFFFAOYSA-N 0.000 description 3
- UUISEXNUHLZEDB-UHFFFAOYSA-N 3-fluorobenzohydrazide Chemical group NNC(=O)C1=CC=CC(F)=C1 UUISEXNUHLZEDB-UHFFFAOYSA-N 0.000 description 3
- DNFLFZXOMTXSCO-UHFFFAOYSA-N 3-methyl-8-phenyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine Chemical compound N1CCN2C(C)=NN=C2C1C1=CC=CC=C1 DNFLFZXOMTXSCO-UHFFFAOYSA-N 0.000 description 3
- SSIPIQQKMYCMHD-UHFFFAOYSA-N 8-benzyl-3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine Chemical compound N1CCN2C(C(F)(F)F)=NN=C2C1CC1=CC=CC=C1 SSIPIQQKMYCMHD-UHFFFAOYSA-N 0.000 description 3
- WLUZTCIMWUHRNW-UHFFFAOYSA-N 8-benzyl-7-hydroxy-3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine Chemical compound ON1CCN2C(=NN=C2C(F)(F)F)C1CC1=CC=CC=C1 WLUZTCIMWUHRNW-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- ASWZNMXNTBXTBZ-UHFFFAOYSA-N C1(=CC=CC=C1)C1N(CCNC1=S)C(=O)OC(C)(C)C Chemical compound C1(=CC=CC=C1)C1N(CCNC1=S)C(=O)OC(C)(C)C ASWZNMXNTBXTBZ-UHFFFAOYSA-N 0.000 description 3
- FMIPOGIESXRHTG-UHFFFAOYSA-N CC1=NN=C2C(NCCN12)C1=CC=C(F)C=C1 Chemical compound CC1=NN=C2C(NCCN12)C1=CC=C(F)C=C1 FMIPOGIESXRHTG-UHFFFAOYSA-N 0.000 description 3
- RBZXOHSUXITYIM-UHFFFAOYSA-N CC1CN2C(=NN=C2C(F)(F)F)C(N1)C1=CC=CC=C1 Chemical compound CC1CN2C(=NN=C2C(F)(F)F)C(N1)C1=CC=CC=C1 RBZXOHSUXITYIM-UHFFFAOYSA-N 0.000 description 3
- IDEXIZAXWJPGMQ-UHFFFAOYSA-N CC1N(CCNC1=S)C(=O)OC(C)(C)C Chemical compound CC1N(CCNC1=S)C(=O)OC(C)(C)C IDEXIZAXWJPGMQ-UHFFFAOYSA-N 0.000 description 3
- ZWOCDCRCMJQBFT-UHFFFAOYSA-N CSC1=NCCN(C1C1=CC=CC=C1)C(=O)OC(C)(C)C Chemical compound CSC1=NCCN(C1C1=CC=CC=C1)C(=O)OC(C)(C)C ZWOCDCRCMJQBFT-UHFFFAOYSA-N 0.000 description 3
- DNLOATGWYHQNPG-QMMMGPOBSA-N C[C@H]1CN2C(CN1)=NN=C2C1=CC=C(C=C1)C(F)(F)F Chemical compound C[C@H]1CN2C(CN1)=NN=C2C1=CC=C(C=C1)C(F)(F)F DNLOATGWYHQNPG-QMMMGPOBSA-N 0.000 description 3
- PASHBNIOESKFEB-NSHDSACASA-N C[C@H]1CN2C(CN1C(=O)OC(C)(C)C)=NN=C2C1=CC=C(F)C=C1 Chemical compound C[C@H]1CN2C(CN1C(=O)OC(C)(C)C)=NN=C2C1=CC=C(F)C=C1 PASHBNIOESKFEB-NSHDSACASA-N 0.000 description 3
- CHOHPRZSNWRQEX-QMMMGPOBSA-N C[C@H]1CN2C=NN=C2CN1C(=O)OC(C)(C)C Chemical compound C[C@H]1CN2C=NN=C2CN1C(=O)OC(C)(C)C CHOHPRZSNWRQEX-QMMMGPOBSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- CBALFSAMBBBIDC-JTQLQIEISA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=CN=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=NC=CN=C1 CBALFSAMBBBIDC-JTQLQIEISA-N 0.000 description 3
- PSSIQQUPMTZWSN-JTQLQIEISA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C=1OC=CC=1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C=1OC=CC=1 PSSIQQUPMTZWSN-JTQLQIEISA-N 0.000 description 3
- UOPWUZHUASGJAP-UHFFFAOYSA-N FC(C1=NN=C2N1CC[N+](=C2)[O-])(F)F Chemical compound FC(C1=NN=C2N1CC[N+](=C2)[O-])(F)F UOPWUZHUASGJAP-UHFFFAOYSA-N 0.000 description 3
- JMPQUVJVYRRQDW-UHFFFAOYSA-N FC(F)C1=NN=C2N1C=CN=C2C1=CC=CC=C1 Chemical compound FC(F)C1=NN=C2N1C=CN=C2C1=CC=CC=C1 JMPQUVJVYRRQDW-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- HVOFEFCMEYKUPG-UHFFFAOYSA-N NCCNC(C(C1=CC=CC=C1)Br)=O Chemical compound NCCNC(C(C1=CC=CC=C1)Br)=O HVOFEFCMEYKUPG-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- HUYREUUJFLHEDE-UHFFFAOYSA-N cyclohexanecarbohydrazide Chemical compound NNC(=O)C1CCCCC1 HUYREUUJFLHEDE-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- OHFIJHDYYOCZME-UHFFFAOYSA-N pyrazine-2-carbohydrazide Chemical compound NNC(=O)C1=CN=CC=N1 OHFIJHDYYOCZME-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- QEFOYONOSVMOSB-ZETCQYMHSA-N tert-butyl (6S)-3-bromo-6-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine-7-carboxylate Chemical compound BrC1=NN=C2N1C[C@@H](N(C2)C(=O)OC(C)(C)C)C QEFOYONOSVMOSB-ZETCQYMHSA-N 0.000 description 3
- XWYOGPGTTFWZAP-UHFFFAOYSA-N tert-butyl 3-oxo-2-phenylpiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(=O)C1C1=CC=CC=C1 XWYOGPGTTFWZAP-UHFFFAOYSA-N 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- KLLYGDXCCNXESW-UHFFFAOYSA-N (2-fluoroacetyl) 2-fluoroacetate Chemical compound FCC(=O)OC(=O)CF KLLYGDXCCNXESW-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- ZZRFDLHBMBHJTI-UHFFFAOYSA-N 1-(oxan-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NN1C1OCCCC1 ZZRFDLHBMBHJTI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OARJXUPBZNUYBG-UHFFFAOYSA-N 2,2-dimethylpropanehydrazide Chemical compound CC(C)(C)C(=O)NN OARJXUPBZNUYBG-UHFFFAOYSA-N 0.000 description 2
- VTGDPGXIJYFMEK-UHFFFAOYSA-N 2,3-dichloro-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(Cl)=C1Cl VTGDPGXIJYFMEK-UHFFFAOYSA-N 0.000 description 2
- MLCNOCRGSBCAGH-UHFFFAOYSA-N 2,3-dichloropyrazine Chemical compound ClC1=NC=CN=C1Cl MLCNOCRGSBCAGH-UHFFFAOYSA-N 0.000 description 2
- ATCRIUVQKHMXSH-UHFFFAOYSA-N 2,4-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1Cl ATCRIUVQKHMXSH-UHFFFAOYSA-N 0.000 description 2
- MXIUWSYTQJLIKE-UHFFFAOYSA-N 2-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC=C1C(Cl)=O MXIUWSYTQJLIKE-UHFFFAOYSA-N 0.000 description 2
- BCHMRNALCJISMZ-UHFFFAOYSA-N 2-[(tert-butylamino)methyl]-6-(4-chlorophenyl)-4-[(7-chloroquinolin-4-yl)amino]phenol Chemical group OC=1C(CNC(C)(C)C)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=CC=1C1=CC=C(Cl)C=C1 BCHMRNALCJISMZ-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- XZUTXPBRISPHPS-UHFFFAOYSA-N 2-methyl-3-(trifluoromethyl)benzoyl chloride Chemical compound CC1=C(C(Cl)=O)C=CC=C1C(F)(F)F XZUTXPBRISPHPS-UHFFFAOYSA-N 0.000 description 2
- PLNNJQXIITYYTN-UHFFFAOYSA-N 2-methylpropanehydrazide Chemical compound CC(C)C(=O)NN PLNNJQXIITYYTN-UHFFFAOYSA-N 0.000 description 2
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- KAJQRKFQQWLHLA-QMMMGPOBSA-N C[C@H]1CN2C(CN1)=NN=C2C1=CC=C(F)C=C1 Chemical compound C[C@H]1CN2C(CN1)=NN=C2C1=CC=C(F)C=C1 KAJQRKFQQWLHLA-QMMMGPOBSA-N 0.000 description 2
- SJXAVZYPNQACKO-ZETCQYMHSA-N C[C@H]1CN2C(CN1)=NN=C2C1=NC=C(F)C=C1 Chemical compound C[C@H]1CN2C(CN1)=NN=C2C1=NC=C(F)C=C1 SJXAVZYPNQACKO-ZETCQYMHSA-N 0.000 description 2
- BGXZBTQKZHWFDR-LURJTMIESA-N C[C@H]1CN2C(CN1)=NN=C2C1=NC=C(F)C=N1 Chemical compound C[C@H]1CN2C(CN1)=NN=C2C1=NC=C(F)C=N1 BGXZBTQKZHWFDR-LURJTMIESA-N 0.000 description 2
- AXOSPXGJAGQINU-NSHDSACASA-N C[C@H]1CN2C(CN1C(=O)OC(C)(C)C)=NN=C2C1=CC=C(C=C1)C(F)(F)F Chemical compound C[C@H]1CN2C(CN1C(=O)OC(C)(C)C)=NN=C2C1=CC=C(C=C1)C(F)(F)F AXOSPXGJAGQINU-NSHDSACASA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 241000206601 Carnobacterium mobile Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LCUNTSKPIDUPRY-JTQLQIEISA-N ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=C(C=C1)C(F)(F)F)F Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1CC=2N(C[C@@H]1C)C(=NN=2)C1=CC(=C(C=C1)C(F)(F)F)F LCUNTSKPIDUPRY-JTQLQIEISA-N 0.000 description 2
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 2
- 208000026292 Cystic Kidney disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- ACMKXSOMVYAVLX-UHFFFAOYSA-N FC1=CC=C(C=C1)C1NCCN2C(=NN=C12)C1CC1 Chemical compound FC1=CC=C(C=C1)C1NCCN2C(=NN=C12)C1CC1 ACMKXSOMVYAVLX-UHFFFAOYSA-N 0.000 description 2
- UZOMDPNPLSPYGU-UHFFFAOYSA-N FC=1C=C(C(=O)NN)C=CC=1C(F)(F)F Chemical group FC=1C=C(C(=O)NN)C=CC=1C(F)(F)F UZOMDPNPLSPYGU-UHFFFAOYSA-N 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 2
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 2
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- KYUUPPKLZSVGMG-UHFFFAOYSA-N cyclobutanecarbohydrazide Chemical compound NNC(=O)C1CCC1 KYUUPPKLZSVGMG-UHFFFAOYSA-N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- DXGIRFAFSFKYCF-UHFFFAOYSA-N propanehydrazide Chemical compound CCC(=O)NN DXGIRFAFSFKYCF-UHFFFAOYSA-N 0.000 description 2
- BAQLNPIEFOYKNB-UHFFFAOYSA-N pyridine-2-carbohydrazide Chemical compound NNC(=O)C1=CC=CC=N1 BAQLNPIEFOYKNB-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- PSJKVBQGZZWWCE-UHFFFAOYSA-N tert-butyl 3-methyl-8-phenyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine-7-carboxylate Chemical compound CC1=NN=C2N1CCN(C2C1=CC=CC=C1)C(=O)OC(C)(C)C PSJKVBQGZZWWCE-UHFFFAOYSA-N 0.000 description 2
- UTVRWZGIHOCOID-ZETCQYMHSA-N tert-butyl N-[(2S)-1-[(2-chloroacetyl)amino]propan-2-yl]carbamate Chemical compound C[C@@H](CNC(=O)CCl)NC(=O)OC(C)(C)C UTVRWZGIHOCOID-ZETCQYMHSA-N 0.000 description 2
- 238000003354 tissue distribution assay Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 108010072897 transcription factor Brn-2 Proteins 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- IMCQXCPTQKOHCY-UHFFFAOYSA-N 2,3-dichloro-5-methylpyrazine Chemical compound CC1=CN=C(Cl)C(Cl)=N1 IMCQXCPTQKOHCY-UHFFFAOYSA-N 0.000 description 1
- LLMLNAVBOAMOEE-UHFFFAOYSA-N 2,3-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1Cl LLMLNAVBOAMOEE-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- FBRJYBGLCHWYOE-UHFFFAOYSA-N 2-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(F)(F)F FBRJYBGLCHWYOE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UDEJUBDPPQVWEX-UHFFFAOYSA-N 2-bromo-2-phenylacetyl chloride Chemical compound ClC(=O)C(Br)C1=CC=CC=C1 UDEJUBDPPQVWEX-UHFFFAOYSA-N 0.000 description 1
- OCLDSIAHVMNJMC-UHFFFAOYSA-N 2-chloro-4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C(Cl)=C1 OCLDSIAHVMNJMC-UHFFFAOYSA-N 0.000 description 1
- XVEAMDNSCPPPCP-UHFFFAOYSA-N 2-fluoro-3-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1F XVEAMDNSCPPPCP-UHFFFAOYSA-N 0.000 description 1
- RIKGRFSGIOOYEK-UHFFFAOYSA-N 2-fluoro-3-(trifluoromethyl)benzoyl chloride Chemical compound FC1=C(C(Cl)=O)C=CC=C1C(F)(F)F RIKGRFSGIOOYEK-UHFFFAOYSA-N 0.000 description 1
- RAAGZOYMEQDCTD-UHFFFAOYSA-N 2-fluorobenzoyl chloride Chemical compound FC1=CC=CC=C1C(Cl)=O RAAGZOYMEQDCTD-UHFFFAOYSA-N 0.000 description 1
- QCICYPQPGJJZGW-UHFFFAOYSA-N 2-hydroxypropanehydrazide Chemical compound CC(O)C(=O)NN QCICYPQPGJJZGW-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- OBNAXEXVXCKFQO-UHFFFAOYSA-N 3,4,5-trifluorobenzohydrazide Chemical group NNC(=O)C1=CC(F)=C(F)C(F)=C1 OBNAXEXVXCKFQO-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- NKGGSFASGFNDDK-UHFFFAOYSA-N 3-(4-fluorophenyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine Chemical compound CC1NCCN2C1=NN=C2C1=CC=C(F)C=C1 NKGGSFASGFNDDK-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FMTDZGCPYKWMPT-UHFFFAOYSA-N 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine Chemical compound C1NCCN2C(C(F)(F)F)=NN=C21 FMTDZGCPYKWMPT-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UVJBNXZJTBKRQB-UHFFFAOYSA-N 3-chloro-2-(trifluoromethyl)pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(C(F)(F)F)=C1Cl UVJBNXZJTBKRQB-UHFFFAOYSA-N 0.000 description 1
- BSPUWRUTIOUGMZ-UHFFFAOYSA-N 3-methylpiperazin-2-one Chemical compound CC1NCCNC1=O BSPUWRUTIOUGMZ-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- PKBGHORNUFQAAW-UHFFFAOYSA-N 4-chlorobenzohydrazide Chemical compound NNC(=O)C1=CC=C(Cl)C=C1 PKBGHORNUFQAAW-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical class OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QWMFKVNJIYNWII-UHFFFAOYSA-N 5-bromo-2-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=C(Br)C=N1 QWMFKVNJIYNWII-UHFFFAOYSA-N 0.000 description 1
- ONIQAPTYIHXUFI-UHFFFAOYSA-N 5-fluoropyridine-2-carbohydrazide Chemical compound NNC(=O)C1=CC=C(F)C=N1 ONIQAPTYIHXUFI-UHFFFAOYSA-N 0.000 description 1
- QJDWNSSLOISUIP-UHFFFAOYSA-N 5-fluoropyrimidine-2-carbohydrazide Chemical group NNC(=O)C1=NC=C(F)C=N1 QJDWNSSLOISUIP-UHFFFAOYSA-N 0.000 description 1
- XULZYUMMNXXBLC-UHFFFAOYSA-N 5-methoxypyridine-2-carbohydrazide Chemical compound COC1=CC=C(C(=O)NN)N=C1 XULZYUMMNXXBLC-UHFFFAOYSA-N 0.000 description 1
- ZWWGWPLNTDADAD-UHFFFAOYSA-N 6-fluoropyridine-2-carbohydrazide Chemical compound NNC(=O)C1=CC=CC(F)=N1 ZWWGWPLNTDADAD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QONZHHQMENMJIU-UHFFFAOYSA-N 8-methyl-3-pyridin-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine Chemical compound CC1NCCN2C1=NN=C2C1=CC=CC=N1 QONZHHQMENMJIU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000251169 Alopias vulpinus Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- IZRVVXSZIBLPHA-UHFFFAOYSA-N C(C(=O)O)(=O)O.C(C#C)(=O)O Chemical compound C(C(=O)O)(=O)O.C(C#C)(=O)O IZRVVXSZIBLPHA-UHFFFAOYSA-N 0.000 description 1
- AXNPSGOKUWXUAT-UHFFFAOYSA-N CC1=NN=C2C(NCCN12)C1=NC=CC=C1 Chemical compound CC1=NN=C2C(NCCN12)C1=NC=CC=C1 AXNPSGOKUWXUAT-UHFFFAOYSA-N 0.000 description 1
- IXSBSXMOBYNRBV-UHFFFAOYSA-N CC1C=2N(CCN1C(=O)OC(C)(C)C)C(=NN=2)C1=NC=CC=C1 Chemical compound CC1C=2N(CCN1C(=O)OC(C)(C)C)C(=NN=2)C1=NC=CC=C1 IXSBSXMOBYNRBV-UHFFFAOYSA-N 0.000 description 1
- NUZFEEMYIBMGTM-NSHDSACASA-N COC1=CC(=NC=C1)C1=NN=C2CN([C@@H](C)CN12)C(=O)OC(C)(C)C Chemical compound COC1=CC(=NC=C1)C1=NN=C2CN([C@@H](C)CN12)C(=O)OC(C)(C)C NUZFEEMYIBMGTM-NSHDSACASA-N 0.000 description 1
- CJPWEOXQMLVRJC-QMMMGPOBSA-N COC1=CC(=NC=C1)C1=NN=C2CN[C@@H](C)CN12 Chemical compound COC1=CC(=NC=C1)C1=NN=C2CN[C@@H](C)CN12 CJPWEOXQMLVRJC-QMMMGPOBSA-N 0.000 description 1
- WXNMJCKNTHPQFY-QMMMGPOBSA-N COC1=CN=C(C=C1)C1=NN=C2CN[C@@H](C)CN12 Chemical compound COC1=CN=C(C=C1)C1=NN=C2CN[C@@H](C)CN12 WXNMJCKNTHPQFY-QMMMGPOBSA-N 0.000 description 1
- IOEMPDQZFLFBJZ-ZETCQYMHSA-N C[C@H]1CN2C(CN1)=NN=C2C1=NC=CC(I)=C1 Chemical compound C[C@H]1CN2C(CN1)=NN=C2C1=NC=CC(I)=C1 IOEMPDQZFLFBJZ-ZETCQYMHSA-N 0.000 description 1
- PCHFAIQVFKKHPG-VIFPVBQESA-N C[C@H]1CN2C(CN1C(=O)C1=C(Cl)C(=C(F)C=C1)C(F)(F)F)=NN=C2C1=C(F)C=C(F)C=C1 Chemical compound C[C@H]1CN2C(CN1C(=O)C1=C(Cl)C(=C(F)C=C1)C(F)(F)F)=NN=C2C1=C(F)C=C(F)C=C1 PCHFAIQVFKKHPG-VIFPVBQESA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- CLWZUISRCONRIJ-UHFFFAOYSA-N Cc1nnc2C(N(CCn12)C(O)=O)c1ccccc1 Chemical compound Cc1nnc2C(N(CCn12)C(O)=O)c1ccccc1 CLWZUISRCONRIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- WXXUKQWRKKTJRR-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C)C1=NC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C)C1=NC=CC=C1 WXXUKQWRKKTJRR-UHFFFAOYSA-N 0.000 description 1
- PLUYODJABXFQED-UHFFFAOYSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C=1OC=CC=1)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1C(C=2N(CC1)C(=NN=2)C=1OC=CC=1)C1=CC=CC=C1 PLUYODJABXFQED-UHFFFAOYSA-N 0.000 description 1
- WXXUKQWRKKTJRR-MRXNPFEDSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C)C1=NC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C)C1=NC=CC=C1 WXXUKQWRKKTJRR-MRXNPFEDSA-N 0.000 description 1
- XOVFDQZVZNCDOR-GOSISDBHSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C1CC1)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@@H](C=2N(CC1)C(=NN=2)C1CC1)C1=CC=C(C=C1)F XOVFDQZVZNCDOR-GOSISDBHSA-N 0.000 description 1
- WXXUKQWRKKTJRR-INIZCTEOSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C)C1=NC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C)C1=NC=CC=C1 WXXUKQWRKKTJRR-INIZCTEOSA-N 0.000 description 1
- XOVFDQZVZNCDOR-SFHVURJKSA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C1CC1)C1=CC=C(C=C1)F Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C1CC1)C1=CC=C(C=C1)F XOVFDQZVZNCDOR-SFHVURJKSA-N 0.000 description 1
- PLUYODJABXFQED-IBGZPJMESA-N ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C=1OC=CC=1)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1[C@H](C=2N(CC1)C(=NN=2)C=1OC=CC=1)C1=CC=CC=C1 PLUYODJABXFQED-IBGZPJMESA-N 0.000 description 1
- LKRYOMVAVRZUMD-UHFFFAOYSA-N ClC1=C(C=CC=C1Cl)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=NC=CC=C1)C Chemical compound ClC1=C(C=CC=C1Cl)C(=O)N1C(C=2N(CC1)C(=NN=2)C1=NC=CC=C1)C LKRYOMVAVRZUMD-UHFFFAOYSA-N 0.000 description 1
- AUEIPAJOBRBKCR-UHFFFAOYSA-N ClC=1C(=NC=CC=1C(=O)N1C(C=2N(CC1)C(=NN=2)C1=NC=CC=C1)C)C(F)(F)F Chemical compound ClC=1C(=NC=CC=1C(=O)N1C(C=2N(CC1)C(=NN=2)C1=NC=CC=C1)C)C(F)(F)F AUEIPAJOBRBKCR-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- JIOUEMPNKALBBP-UHFFFAOYSA-N FC1=CC=C(C=C1)C1=NN=C2N1CCN(C2C)C(=O)OC(C)(C)C Chemical compound FC1=CC=C(C=C1)C1=NN=C2N1CCN(C2C)C(=O)OC(C)(C)C JIOUEMPNKALBBP-UHFFFAOYSA-N 0.000 description 1
- CMPWLGLFBPCHPX-SFHVURJKSA-N FC1=CC=C(C=C1)[C@H]1C=2N(CCN1C(=O)C1=C(C(=CC=C1)C(F)(F)F)C)C(=NN=2)C Chemical compound FC1=CC=C(C=C1)[C@H]1C=2N(CCN1C(=O)C1=C(C(=CC=C1)C(F)(F)F)C)C(=NN=2)C CMPWLGLFBPCHPX-SFHVURJKSA-N 0.000 description 1
- FMQDAEDAUSZRKL-ZETCQYMHSA-N FC1=CC=CC(=N1)C1=NN=C2N1C[C@@H](NC2)C Chemical compound FC1=CC=CC(=N1)C1=NN=C2N1C[C@@H](NC2)C FMQDAEDAUSZRKL-ZETCQYMHSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- KOIHQXKGNGRFSI-UHFFFAOYSA-N IC1=CC(=NC=C1)C(=O)NN Chemical compound IC1=CC(=NC=C1)C(=O)NN KOIHQXKGNGRFSI-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- LBINNJYFKRBUCY-UHFFFAOYSA-N [2-chloro-3-(trifluoromethyl)phenyl]-(5-methyl-3-phenyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)methanone Chemical compound ClC1=C(C=CC=C1C(F)(F)F)C(=O)N1CC=2N(C(C1)C)C(=NN=2)C1=CC=CC=C1 LBINNJYFKRBUCY-UHFFFAOYSA-N 0.000 description 1
- PPNVGUHTGFXKQD-UHFFFAOYSA-N [8-benzyl-3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-[2-chloro-3-(trifluoromethyl)phenyl]methanone Chemical compound C(C1=CC=CC=C1)C1C=2N(CCN1C(=O)C1=C(C(=CC=C1)C(F)(F)F)Cl)C(=NN=2)C(F)(F)F PPNVGUHTGFXKQD-UHFFFAOYSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- VNWKTOKETHGBQD-BJUDXGSMSA-N carbane Chemical compound [11CH4] VNWKTOKETHGBQD-BJUDXGSMSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- MMCOUVMKNAHQOY-UHFFFAOYSA-N carbonoperoxoic acid Chemical class OOC(O)=O MMCOUVMKNAHQOY-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PSHRANCNVXNITH-UHFFFAOYSA-N dimethylamino acetate Chemical compound CN(C)OC(C)=O PSHRANCNVXNITH-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- XZBIXDPGRMLSTC-UHFFFAOYSA-N formohydrazide Chemical compound NNC=O XZBIXDPGRMLSTC-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- PZJSZBJLOWMDRG-UHFFFAOYSA-N furan-2-ylboronic acid Chemical compound OB(O)C1=CC=CO1 PZJSZBJLOWMDRG-UHFFFAOYSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000053195 human P2RX7 Human genes 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical compound I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 1
- 238000010884 ion-beam technique Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- SCEZYJKGDJPHQO-UHFFFAOYSA-M magnesium;methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC=C1 SCEZYJKGDJPHQO-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical class [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- OIRDBPQYVWXNSJ-BJUDXGSMSA-N methyl trifluoromethanesulfonate Chemical compound [11CH3]OS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-BJUDXGSMSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- VLZLOWPYUQHHCG-UHFFFAOYSA-N nitromethylbenzene Chemical compound [O-][N+](=O)CC1=CC=CC=C1 VLZLOWPYUQHHCG-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N ortho-methoxybenzoic acid Natural products COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 125000005541 phosphonamide group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- JESDFELYLDMNBN-JTQLQIEISA-N tert-butyl (6S)-3-(furan-2-yl)-6-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine-7-carboxylate Chemical compound O1C(=CC=C1)C1=NN=C2N1C[C@@H](N(C2)C(=O)OC(C)(C)C)C JESDFELYLDMNBN-JTQLQIEISA-N 0.000 description 1
- KKVKQTLLEBWZTR-UHFFFAOYSA-N tert-butyl 2-methyl-3-oxopiperazine-1-carboxylate Chemical compound CC1N(C(=O)OC(C)(C)C)CCNC1=O KKVKQTLLEBWZTR-UHFFFAOYSA-N 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- PDAFIZPRSXHMCO-LURJTMIESA-N tert-butyl n-[(2s)-1-hydroxypropan-2-yl]carbamate Chemical compound OC[C@H](C)NC(=O)OC(C)(C)C PDAFIZPRSXHMCO-LURJTMIESA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 125000006337 tetrafluoro ethyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
Abstract
Description
並びにその製薬学的に許容可能な塩に関する。
(式中、
Raは、
R1は、ハロ又はC1〜C3アルキルであり、
R2は、H、ハロ及びC1〜C3ペルハロアルキルからなる群から独立して選択され、
R3は、H又はハロであり、
R4は、ハロであり、
R5は、ハロ又はC1〜C3ペルハロアルキルであり、
Rbは、以下からなる群から独立して選択され、
R6、R9、R10、R12、R14は、独立して、H又はハロであり、
R7、R8、R13は、H、ハロ及びOC1〜C3アルキルからなる群から独立して選択され、
R11は、H、ハロ及びC1〜C3ペルハロアルキルからなる群から独立して選択され、
Rcは、以下からなる群から選択され、
ただし、Rc、Rd及びReのうちの少なくとも1つは、Hではない。)
並びにその製薬学的に許容可能な塩。
(式中、
Raは、
R1は、ハロ又はC1〜C3アルキルであり、
R2は、H、ハロ及びC1〜C3ペルハロアルキルからなる群から独立して選択され、
R3は、H又はハロであり、
R4は、ハロであり、
R5は、ハロ又はC1〜C3ペルハロアルキルであり、
Rbは、以下からなる群から独立して選択され、
R6、R9、R10、R12、R14は、独立して、H又はハロであり、
R7、R8、R13は、H、ハロ及びOC1〜C3アルキルからなる群から独立して選択され、
R11は、H、ハロ及びC1〜C3ペルハロアルキルからなる群から独立して選択され、
Rcは、以下からなる群から選択され、
ただし、Rc、Rd及びReのうちの少なくとも1つは、Hではない。)
並びにその製薬学的に許容可能な塩から選択される、有効量の少なくとも1つの化合物
(式中、
Raは、
R1は、ハロ又はC1〜C3アルキルであり、
R2は、H、ハロ及びC1〜C3ペルハロアルキルからなる群から独立して選択され、
R3は、H又はハロであり、
R4は、ハロであり、
R5は、ハロ又はC1〜C3ペルハロアルキルであり、
Rbは、以下からなる群から独立して選択され、
R6、R9、R10、R12、R14は、独立して、H又はハロであり、
R7、R8、R13は、H、ハロ及びOC1〜C3アルキルからなる群から独立して選択され、
R11は、H、ハロ及びC1〜C3ペルハロアルキルからなる群から独立して選択され、
Rcは、以下からなる群から選択され、
ただし、Rc、Rd及びReのうちの少なくとも1つは、Hではない。)投与することを含む、方法である。
基PGは、保護基を表す。当業者は、所望の反応と適合性である適切な保護基を選択するであろう。保護基は、その後の都合のよい段階で、当該技術分野で周知の方法を用いて除去することができる。あるいは、最終的に望ましい置換基の代わりに、反応スキーム全体にわたって担持されかつ適宜望ましい置換基と置き換わり得る適切な基を用いる必要がある可能性もある。このような化合物、前駆体又はプロドラッグもまた、本発明の範囲内である。好ましい保護基の例には、カルバメート基、ベンジル基及び置換ベンジル基が挙げられる。特に好ましい保護基は、tert−ブチルオキシカルボニル及びベンジルである。
移動相:0.2%イソプロピルアミン含有EtOH 25.5mL/分、CO2 59.5mL/分
検出:UV254nm
移動相:0.2%イソプロピルアミン含有EtOH 25.5mL/分、CO2 59.5mL/分
検出:UV254nm
実施例4:(2−クロロ−3−(トリフルオロメチル)フェニル)(5−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン。
Boc−L−アラニノール(10.9g、61.7mmol)のエーテル(300mL)中0℃溶液に、トリエチルアミン(12.8mL、92.5mmol)と、続いてメタンスルホニルクロリド(4.8mL、61.7mmol)とを加え、混合物を1時間攪拌した。水を加え、得られた反応混合物をDCMで抽出した。有機層を合わせ、乾燥させ、濃縮し、得られた残渣をDMF(100mL)中に溶解した。得られた溶液に、アジ化ナトリウム(8.0g、123.4mmol)を加え、反応混合物を70℃まで18時間加熱した。反応混合物を室温まで冷却し、水を加え、反応混合物をEtOAcで抽出した。有機層を合わせ、ブラインで洗浄し、乾燥させ、濃縮し、フラッシュカラムクロマトグラフィー(0〜50% EtOAc/ヘキサン)により精製して、(S)−tert−ブチル(1−アジドプロパン−2−イル)カルバメート(8.5g)を得た。1H NMR(400MHz、DMSO)δ 7.05〜6.84(d、J=8.0Hz、1H)、3.72〜3.55(m、1H)、3.26〜3.19(d、J=6.1Hz、2H)、1.42〜1.36(s、9H)、1.06〜0.99(d、J=6.8Hz、3H)。
(S)−tert−ブチル(1−アジドプロパン−2−イル)カルバメート(8.5g、42.4mmol)のEtOAc(300mL)中溶液に、10% Pd/C(4.5g)を加え、反応混合物を0.4MPa((60psi))のH2雰囲気下に2時間置いた。反応混合物をセライトパッドに通して濾過し、濃縮し、得られた残渣をDCM(300mL)中に取った。得られた溶液を−78℃まで冷却し、トリエチルアミン(8.9mL)と、続いてクロロアセチルクロリド(3.5mL、44.6mmol)とを加えた。反応混合物を−78℃で20分間攪拌し、次いで、0℃まで加温して1時間攪拌した。水を加え、得られた反応混合物をDCMで抽出した。有機層を合わせ、ブラインで洗浄し、乾燥させ、濃縮し、フラッシュカラムクロマトグラフィー(0〜100% EtOAc/ヘキサン)により精製して、(S)−tert−ブチル(1−(2−クロロアセトアミド)プロパン−2−イル)カルバメート(7.3g)を得た。1H NMR(400MHz、DMSO)δ 8.28〜8.10(s、1H)、6.79〜6.60(d、J=8.2Hz、1H)、4.16〜3.97(s、2H)、3.64〜3.48(m、1H)、3.13〜2.99(m、2H)、1.44〜1.30(s、9H)、1.05〜0.91(d、J=6.7Hz、3H)。
(S)−Tert−ブチル(1−(2−クロロアセトアミド)プロパン−2−イル)カルバメート(7.3g、29.1mmol)をトリフルオロ酢酸(20mL)中に溶解し、15分間攪拌した。反応混合物を濃縮し、得られた残渣をTHF(100mL)中に溶解した。得られた溶液にK2CO3(20.1g、145.6mmol)を加え、反応混合物を20時間還流させた。反応混合物を60℃まで冷却し、触媒DMAPと、続いてBOC無水物(12.5mL、58.2mmol)とを加えた。反応混合物を12時間攪拌し、水を加え、得られた反応混合物をEtOAcで抽出した。有機層を合わせ、乾燥させ、濃縮し、フラッシュカラムクロマトグラフィー(0〜50% iPrOH/EtOAc)により精製して、(S)−tert−ブチル2−メチル−5−オキソピペラジン−1−カルボキシレート(4.6g)を得た。1H NMR(400MHz、DMSO)δ 8.08〜7.90(s、1H)、4.31〜4.09(s、1H)、4.00〜3.87(d、J=17.9Hz、1H)、3.63〜3.51(d、J=17.8Hz、1H)、3.37〜3.33(m、1H)、3.04〜2.93(ddd、J=12.7、4.9、2.5Hz、1H)、1.46〜1.35(s、9H)、1.15〜1.06(d、J=6.7Hz、3H)。
(S)−tert−ブチル2−メチル−5−オキソピペラジン−1−カルボキシレート(1.3g、6.1mmol)のDCM(31mL)中溶液に、トリメチルオキソニウムテトラフルオロボレート(1.0g、6.8mmol)を加え、反応混合物を室温で6時間攪拌した。4−フルオロベンゾヒドラジド(1.2g、8.0mmol)を加え、反応混合物を室温で終夜攪拌した。穏やかなN2気流により反応混合物を濃縮し、得られた残渣をジオキサン(15mL)中に溶解した。得られた溶液に炭酸水素ナトリウム飽和水溶液(15mL)を加え、反応混合物を12時間還流させた。反応混合物を室温まで冷却し、EtOAcで希釈し、水で洗浄し、乾燥させ、濃縮し、フラッシュカラムクロマトグラフィー(0〜10% MeOH/DCM)により精製して、(S)−tert−ブチル3−(4−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−カルボキシレート(1.2g)を得た。MS(ESI)C17H21FN4O2の質量計算値、332.4;m/z実測値、333.2[M+H]+。
(S)−Tert−ブチル3−(4−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−カルボキシレート(0.2g、0.6mmol)をトリフルオロ酢酸中に溶解し、室温で20分間攪拌した。反応混合物を濃縮し、得られた残渣を更に精製することなく使用した。
(S)−tert−ブチル2−メチル−5−オキソピペラジン−1−カルボキシレート(1.2g、5.6mmol)のTHF(20mL)中溶液に、ローソン試薬(2.6g、6.2mmol)を加え、反応混合物を80℃まで1時間加熱した。反応混合物を濃縮し、フラッシュカラムクロマトグラフィー(0〜50% EtOAc/ヘキサン)により精製して、微量の残留不純物を含む(S)−tert−ブチル2−メチル−5−チオキソピペラジン−1−カルボキシレートを得た。1H NMR(400MHz、DMSO)δ 10.64〜10.46(s、1H)、4.48〜4.31(d、J=18.9Hz、1H)、4.31〜4.12(s、1H)、4.11〜3.93(m、1H)、3.90〜3.74(m、1H)、3.20〜3.06(m、1H)、1.48〜1.35(s、9H)、1.09〜1.02(d、J=6.6Hz、3H)。
(S)−tert−ブチル2−メチル−5−チオキソピペラジン−1−カルボキシレート(350mg、1.52mmol)のn−ブタノール(3mL)中溶液に、4−(トリフルオロメチル)ベンゾヒドラジド(479mg、2.28mmol)を加え、反応混合物を140℃まで48時間加熱した。反応混合物を室温まで冷却し、メタノール(10mL)で希釈した。BOC無水物(0.65mL、3.04mmol)を加え、反応混合物を5時間攪拌した。反応混合物をEtOAcで希釈し、水で洗浄し、乾燥させ、濃縮し、フラッシュカラムクロマトグラフィー(0〜100% EtOAc/ヘキサン)により精製して、(S)−tert−ブチル6−メチル−3−(4−(トリフルオロメチル)フェニル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−カルボキシレート(375mg)を得た。
(S)−tert−ブチル6−メチル−3−(4−(トリフルオロメチル)フェニル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−カルボキシレートをトリフルオロ酢酸中に溶解し、室温で10分間攪拌した。反応混合物を濃縮して、(S)−6−メチル−3−(4−(トリフルオロメチル)フェニル)−5,6,7,8−テトラヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジンを得た。これを更に精製することなく使用した。
(S)−tert−ブチル2−メチル−5−チオキソ−ピペラジン−1−カルボキシレート(中間体26A、0.5g、2.17mmol)のエタノール(5mL)中溶液に、4−メトキシ−ピリジン−2−カルボン酸ヒドラジド(435mg、2.61mmol)を加えた。反応混合物をQ−TUBEで密閉管中150℃で12時間加熱した。次いで、溶媒を蒸発させ、粗生成物をカラムクロマトグラフィー(シリカ、MeOH/EtOAc 0:100〜10:90)により精製した。所望のフラクションを回収し、溶媒を蒸発させて、(S)−tert−ブチル3−(4−メトキシ−2−ピリジル)−6−メチル−6,8−ジヒドロ−5H−[1,2,4]トリアゾロ[4,3−a]ピラジン−7−カルボキシレートをオフホワイト固体として得、これを更に精製することなく次の工程に使用した。
(S)−tert−ブチル3−(4−メトキシ−2−ピリジル)−6−メチル−6,8−ジヒドロ−5H−[1,2,4]トリアゾロ[4,3−a]ピラジン−7−カルボキシレート(457mg、1.32mmol)のCH2Cl2(2.5mL)中の混合物に、トリフルオロ酢酸(2.5mL、32.67mmol)を加えた。溶液を室温で15分間攪拌し、次いで、混合物を飽和NaHCO3水溶液で塩基性化し、CH2Cl2で抽出した。有機層を分離し、乾燥させ(Na2SO4)、濾過し、溶媒を減圧下で濃縮して、(S)−3−(4−メトキシ−2−ピリジル)−6−メチル−5,6,7,8−テトラヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン(121mg、37.3%)をオフホワイト固体として得た。
(S)−3−(4−メトキシ−2−ピリジル)−6−メチル−5,6,7,8−テトラヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン(121mg、0.49mmol)及びトリエチルアミン(0.171mL、1.23mmol)のCH2Cl2中の攪拌溶液に、2,3−ジクロロベンゾイルクロリド(103.3mg、0.49mmol)を窒素下0℃で加えた。反応混合物を室温までゆっくりと昇温させ、1時間攪拌した。反応混合物を水でクエンチし、CH2Cl2(1.5mL)で抽出した。有機層を分離し、乾燥させ(Na2SO4)、濾過し、溶媒を減圧下で濃縮した。粗生成物をカラムクロマトグラフィー(シリカ、MeOH/EtOAc 0:100〜10:90)により精製し、所望のフラクションを回収し、溶媒を蒸発させた。残渣をカラムクロマトグラフィー(シリカ、CH3CN/CH2Cl2 0/100〜100/0)により更に精製した。所望のフラクションを回収し、溶媒を蒸発させた。残渣をジイソプロピルエーテルでトリチュレートして、(S)−(2,3−ジクロロフェニル)(3−(4−メトキシピリジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン(81mg、39.3%)をオフホワイト固体として得た。1H NMR(400MHz、CDCl3)δ ppm 1.19(d、J=6.9Hz、0.90H)、1.37(d、J=6.9Hz、0.60H)、1.38(d、J=6.9Hz、0.30H)、1.41(d、J=7.2Hz、1.20H)、3.93(s、0.90H)、3.94(s、2.10H)、4.05〜4.17(m、0.50H)、4.21(dd、J=13.5、4.5Hz、0.20H)、4.38〜4.49(m、0.80H)、4.54〜4.75(m、1.10H)、4.77(d、J=17.1Hz、0.40H)、4.89(d、J=13.6Hz、0.20H)、5.02〜5.19(m、0.80H)、5.49〜5.60(m、0.50H)、5.80(d、J=18.3Hz、0.30H)、5.94(d、J=18.3Hz、0.20H)、6.87(ddd、J=12.5、5.8、2.5Hz、1H)、7.17〜7.39(m、2H)、7.54〜7.60(m、1H)、7.83〜7.91(m、1H)、8.31〜8.37(m、0.40H)、8.43(d、J=5.8Hz、0.60H)。MS(ESI):C19H17Cl2N5O2の質量計算値、417.1;m/z実測値、418.3[M+H]+。[α]=+62.4°(589nm、c0.42w/v%、DMF、20℃)。
HPLC分析は、LaChrom Elite HPLCシステム(Hitachi(Armstadt,Germany))にUV分光計(220nmに設定)を接続して実施した。放射標識化合物の分析のために、UV検出器を通過した後のHPLC溶出液を、マルチチャンネルアナライザーを接続した8cm(3インチ)遮蔽NaI(Tl)シンチレーション検出器(Gabi box,Raytest(Straubenhardt,Germany))に導入した。GINA Starデータ収集システム(Raytest(Straubenhardt,Germany))を使用して、出力シグナルを記録し、分析した。生体内分布試験、細胞吸収実験及び放射性代謝物分析におけるサンプル中の放射能は、マルチチャンネルアナライザーを連結した3インチNaI(Tl)ウェル型結晶を備える自動ガンマカウンター(Wallac 2480 Wizard,Wallac(Turku,Finland))を用いて定量化した。結果は、背景放射、物理的減衰及び計数管不感時間について補正した。
生体内分布試験は、健康な雌のWistarラット(体重185〜220g)にて、トレーサー注入後2分、30分及び60分(n=3/時点)に実施した。イソフルラン(酸素中2.5%、流速1L/分)でマウスに麻酔をかけ、尾静脈から放射リガンドを注入した。指定時点で断頭によって動物を屠殺した。風袋を量った管中に血液及び主要な器官を採取し、秤量した。切開した器官及び血液の放射能を、自動ガンマカウンターを用いて測定した。血液の全放射能の計算には、血液の質量を体重の7%であると仮定した。
表2は、放射トレーサー注入後2分、30分、60分時点における、種々の器官及び体液での注入量パーセンテージ(%ID)を示す。血液中には、注入後2分で注入量の10.0%が検出され、トレーサー注入後60分には5.3%までクリアランスされた。[11C]55の脳における初期の全吸収量は、注入後2分で0.6%であり、トレーサー注入後60分には0.4%までクリアランスされた。トレーサー注入後60分で、注入量の43.8%が肝臓及び腸中に保持された。放射トレーサーの尿中排出は最少であり、注入後60分での尿及び腎臓におけるIDは2.9%であった。
トレーサー注入後30分時点における、正常な雌のWistarラット(n=2)の血漿中の[11C]55放射性代謝物を定量した。Chromolith C18カラムを0.05M NaOAc(pH5.5)(A)とCH3CN(B)のグラジエント混合物で溶出した(0〜4分:アイソクラティック0% B及び流速0.5mL/分;4〜14分:直線グラジエント0% B〜90% B及び流速1mL/分;14〜17分:アイソクラティック90% B及び流速1mL/分)。UV検出は、220nmで行った。再構成ラジオクロマトグラムは、未変化(intact)[11C]55の10分での溶出と、極性放射性代謝物の2分での溶出とに対応する2つのピークを示した(クロマトグラム図示せず)。放射性トレーサー注入から30分後に血漿中で回収された放射能の70±6%が未変化トレーサーの形態であり、30±6%が極性放射性代謝物(複数可)の形態であった。未変化トレーサー後に溶出した親油性の高い放射性代謝物のフラクションは、ごくわずかであった(<1.5%)。
トレーサー注入後30分時点における、正常な雌のWistarラット(n=2)の灌流大脳及び小脳中の[11C]55放射性代謝物を定量した。XBridge分析カラム(C18、5μm、3×100mm;Waters)を用いて、0.05M酢酸ナトリウム(pH5.5)とCH3CN(65:35v/v)の混合物により0.8mL/分の流速で溶出して、ホモジネートを分析した。UV検出を220nmで実施した。トレーサー注入後30分時点における灌流ラット小脳及び大脳HPLC分析による再構成ラジオクロマトグラムは、未変化[11C]55の9分での溶出に対応する放射能ピークを1つのみ示した(クロマトグラム図示せず)。極性及び親油性の高い放射性代謝物のフラクションは両方とも、ごくわずかであった(<2%)。
b 全骨組織推定値に対して算出(%ID/g骨*体重*0.12)
本発明の化合物のラット及びヒトP2X7受容体についてのインビトロ親和性を、ヒト末梢血単核細胞(PBMC)、ヒト全血アッセイ、組換えヒトP2X7細胞及び組換えラットP2X7細胞におけるCa2+フラックス及び放射リガンド結合アッセイを用いて決定した。表6において、データセルが空白のままである場合、この化合物をそのアッセイにおいて試験しなかったことを意味する。表2において表されるデータは、1回の測定からの値を表す場合もあれば、実験を2回以上行った場合には、2〜12回の間の平均値を表すデータの場合もある。
ヒト血液を、血液ドナープログラムを介して収集した。PBMCを、血液から、Ficoll密度勾配技術を用いて単離した。簡潔に述べれば、血液をFicoll溶液の上に重層し、2000rpmで室温にて20分間遠心分離した。バフィー層(赤血球と血漿との間)を注意深く吸引によって収集し、PBSで洗浄し、再び、1500rpmで15分間遠心分離した。得られた細胞ペレットを、洗浄し、96ウェルプレート上に、実験のために置いた。ヒト全血実験の場合、ヒト血液150μLを96ウェルプレートで平板培養した。リポ多糖類(LPS)(30ng/mL)を各ウェルに加え、1時間にわたってインキュベートした。次いで、試験化合物を加え、30分間にわたってインキュベートした。次いで、P2X7アゴニストである2’(3’)−O−(4−ベンゾイルベンゾイル)アデノシン5’−三リン酸(Bz−ATP)を、0.5mM(PBMC)又は1mM(血液)の終濃度で加えた。細胞を、更に1.5時間にわたりインキュベートした。その時点で、上清を採取して、酵素結合イムノソルベントアッセイ(ELISA)に関する製造元のプロトコルを用いてIL−1βアッセイ用に保存した。データは、%対照として表記し、対照は、LPS+Bz−ATP試料及びLPSのみの試料におけるIL−1β放出の差として定義される。データを濃度に対する反応(%対照)としてプロットして、IC50値を得た。表2において、このデータは、PBMC 1μM(%対照)及びPBMC 10μM(%対照)及びヒト全血IC50(μM)によって表す。データを分析し、Graphpad Prism5においてグラフ化する。分析のために、各濃度点を、三連の値から平均化し、平均値を、Graphpad Prismにおいてプロットする。次いで、各化合物についてのIC50を、3DXにアップロードした。
(a)Ca2+フラックス:組換えヒト又はラットP2X7チャネルを発現する1321N1細胞は、10%ウシ胎仔血清(FBS)及び適切な選択マーカーを添加したHyQ DME/(HyClone/ダルベッコ改変イーグル培地)高グルコース培地中で培養した。細胞を、25000個/ウェル(96ウェル透明底黒壁プレート)の密度で、100μL容量/ウェルにて撒いた。実験日に、細胞プレートを、130mM NaCl、2mM KCl、1mM CaCl2、1mM MgCl2、10mM HEPES、5mM グルコースを含むアッセイ緩衝液(pH7.40及び300mOs)で洗浄した。洗浄後、細胞を、Calcium−4染料(Molecular Device)と共にローディングし、暗所にて60分間インキュベートした。試験化合物を、そのままのDMSO中の試験濃度の250倍にて調製した。中間体96ウェル化合物プレートを、1.2μLの本化合物を300μLのアッセイ緩衝液中に移すことによって調製した。更に3倍の希釈が、50μL/ウェルの本化合物プレートを100μL/ウェルの細胞プレートに移す際に起きた。細胞を、試験化合物と共にインキュベートし、30分間にわたって染色した。Calcium染料蛍光を、FLIPRにおいてモニタリングし、細胞を、50μL/ウェルのBzATP(終濃度は250μM BzATPである(ヒト及びラット))の添加によってチャレンジした。蛍光変化を、アゴニストの添加の180秒後に測定した。Origin7ソフトウェアを用いて、ピーク蛍光をBzATP濃度の関数としてプロットし、得られたIC50を、表2の項目見出し「FLIPR(ヒト)IC50(μM)」及び「FLIPR(ラット)IC50(μM)」の下に示す。
(b)放射リガンド結合:ヒト又はラットP2X7−1321N1細胞を収集して−80℃で凍結した。実験当日、公表された標準的な方法に従って細胞膜調製物を作製した。全アッセイ体積は、100μLであった:10μL化合物(10×)+(b)40μLトレーサー(2.5×)+50μL膜(2×)。アッセイのために使用したトレーサーは、トリチウム化A−804598であった。化合物を、文献に記載のように調製した。(Donnelly−Roberts,D.Neuropharmacology 2008,56(1),223〜229)。化合物、トレーサー及び膜を、1時間にわたって4℃にてインキュベートした。アッセイを、濾過(0.3% PEIに事前に浸したGF/Bフィルター)によって停止させ、洗浄緩衝液(Tris−HCl 50mM)で洗浄した。結合アッセイから得たIC50をトレーサー濃度及びトレーサーの親和性に関して補正して、試験化合物の親和性(Ki)を誘導した。データを、表6の項目見出し「P2X7ヒトKi(μM)」及び「P2X7ラットKi(μM)」の下に示す。データを分析し、Graphpad Prism5においてグラフ化する。分析のために、各濃度点を、三連の値から平均化し、平均値を、Graphpad Prismにおいてプロットする。
Claims (55)
- 式(I)の化合物:
並びにその製薬学的に許容可能な塩。
(式中、
Raは、
R1は、ハロ又はC1〜C3アルキルであり、
R2は、H、ハロ及びC1〜C3ペルハロアルキルからなる群から独立して選択され、
R3は、H又はハロであり、
R4は、ハロであり、
R5は、ハロ又はC1〜C3ペルハロアルキルであり、
Rbは、以下からなる群から独立して選択され、
R6、R9、R10及びR12は、独立して、H又はハロであり、
R7及びR13は、H、ハロ及びOC1〜C3アルキルからなる群から独立して選択され、
R8は、H、ハロ、OH及びOC1〜C3アルキルからなる群から独立して選択され、
R11は、H、ハロ及びC1〜C3ペルハロアルキルからなる群から独立して選択され、
Rcは、以下からなる群から選択され、
ただし、Rc、Rd及びReのうちの少なくとも1つは、Hではない。) - Raが
- Raが
- Raが
- Raが
- Raが
- Raが
- Raが
- Raが
- Raが
- Raが
- Raが
- Raが
- Rbが
- Rbが
- Rbが
C3〜C6シクロアルキル及びC1〜C4アルキル
からなる群から独立して選択される、請求項1に記載の化合物。 - Rbが
- Rbが
- Rbが
- Rbが
- Rbが
- Rbが
- Rbが
- Rbが
- Rbが
- Rbが
- Rbが
- RcがH又はCH3である、請求項1に記載の化合物。
- Rcが以下からなる群から選択される、請求項1に記載の化合物。
- Rcが
- Rcが
- RdがCH3である、請求項1に記載の化合物。
- ReがCH3である、請求項1に記載の化合物。
- RcがCH3であり、Rd及びReがHである、請求項1に記載の化合物。
- RdがCH3であり、Rc及びReがHである、請求項1に記載の化合物。
- ReがCH3であり、Rc及びRdがHである、請求項1に記載の化合物。
- Raが
- Raが
- Raが
- Raが
- Raが
- Raが
- Raが
- 以下からなる群より選択される化合物:
(2,3−ジクロロフェニル)(8−メチル−3−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2,3−ジクロロフェニル)(8−メチル−3−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(8−メチル−3−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
2−クロロ−3−(トリフルオロメチル)フェニル)(5−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2,3−ジクロロフェニル)(5−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(4−フルオロフェニル)−5−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2,3−ジクロロフェニル)(3−(4−フルオロフェニル)−5−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(4−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2,3−ジクロロフェニル)(3−(4−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2−クロロ−3−(トリフルオロメチル)フェニル)(6−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2,3−ジクロロフェニル)(6−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2,3−ジクロロフェニル)(6−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(6−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−クロロ−3−(トリフルオロメチル)フェニル)(6−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(6−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(3−クロロ−2−(トリフルオロメチル)ピリジン−4−イル)(8−メチル−3−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2−クロロ−3−(トリフルオロメチル)フェニル)(8−メチル−3−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2,3−ジクロロフェニル)(3−(4−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(4−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2−フルオロ−3−(トリフルオロメチル)フェニル)(8−メチル−3−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(4−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(6−メチル−3−(ピラジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(6−メチル−3−(ピラジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(フラン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(4−フルオロフェニル)−8−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(6−メチル−3−(4−(トリフルオロメチル)フェニル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(6−メチル−3−(4−(トリフルオロメチル)フェニル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(3−フルオロ−4−(トリフルオロメチル)フェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(3−フルオロ−4−(トリフルオロメチル)フェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(6−メチル−3−(3,4,5−トリフルオロフェニル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(6−メチル−3−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(4−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2,3−ジクロロフェニル)(5−メチル−3−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2−クロロ−3−(トリフルオロメチル)フェニル)(8−メチル−3−(4−(トリフルオロメチル)フェニル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2−クロロ−3−(トリフルオロメチル)フェニル)(8−メチル−3−(ピラジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(4−クロロフェニル)−8−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(2−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(2−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロ−4−フルオロフェニル)(3−(2−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(3−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(3−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロ−4−フルオロフェニル)(3−(3−フルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(2,3−ジフルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(2,3−ジフルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロ−4−フルオロフェニル)(3−(2,3−ジフルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(3,4−ジフルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(3,4−ジフルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロ−4−フルオロフェニル)(3−(3,4−ジフルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(2,4−ジフルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(2,4−ジフルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロ−4−フルオロフェニル)(3−(2,4−ジフルオロフェニル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2−クロロ−3−(トリフルオロメチル)フェニル)(3−メチル−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(6−フルオロピリジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(4−メトキシピリジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2−クロロフェニル)(6−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(3,4−ジフルオロ−2−メチルフェニル)(6−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2−クロロ−4−フルオロフェニル)(6−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(2,3−ジクロロピリジン−4−イル)(6−メチル−3−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(3−シクロヘキシル−8−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)(2,3−ジクロロフェニル)メタノン;
(2−クロロ−3−(トリフルオロメチル)フェニル)(3−シクロヘキシル−8−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(3−シクロヘキシル−8−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)(2,3−ジクロロ−4−フルオロフェニル)メタノン;
(3−シクロプロピル−8−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)(2,3−ジクロロフェニル)メタノン;
(3−シクロプロピル−8−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)(2,3−ジクロロ−4−フルオロフェニル)メタノン;
(2−クロロ−3−(トリフルオロメチル)フェニル)(3−シクロプロピル−8−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−メチル−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−メチル−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(4−フルオロピリジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(5−フルオロピリジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(5−フルオロピリジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
((S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(5−メトキシピリジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(5−メトキシピリジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(5−フルオロピリミジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(5−フルオロピリミジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(±)−(2−クロロ−3−(トリフルオロメチル)フェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−シクロプロピル−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−シクロプロピル−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(5−メトキシピリミジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(±)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(フラン−2−イル)−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(±)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(1−ヒドロキシエチル)−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(3−(tert−ブチル)−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)(2−クロロ−3−(トリフルオロメチル)フェニル)メタノン;
(S)−(3−(tert−ブチル)−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)(2−クロロ−3−(トリフルオロメチル)フェニル)メタノン;
(R)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(フラン−2−イル)−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(フラン−2−イル)−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(±)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−メチル−8−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−エチル−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−エチル−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−イソプロピル−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−イソプロピル−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(±)−(2,3−ジクロロフェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−メチル−8−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−メチル−8−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−シクロブチル−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−シクロブチル−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R*)−(2−クロロ−4−フルオロ−3−(トリフルオロメチル)フェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S*)−(2−クロロ−4−フルオロ−3−(トリフルオロメチル)フェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−クロロ−3−(トリフルオロメチル)フェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R*)−(3−クロロ−2−(トリフルオロメチル)ピリジン−4−イル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S*)−(3−クロロ−2−(トリフルオロメチル)ピリジン−4−イル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(±)−(2−クロロ−3−(トリフルオロメチル)フェニル)(8−(4−フルオロフェニル)−3−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2,3−ジクロロフェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2,3−ジクロロフェニル)(8−(4−フルオロフェニル)−3−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(8−(4−フルオロフェニル)−3−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−シクロプロピル−8−(4−フルオロフェニル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−シクロプロピル−8−(4−フルオロフェニル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(ジフルオロメチル)−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(3−(ジフルオロメチル)−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2,3−ジクロロフェニル)(3−(ジフルオロメチル)−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(ジフルオロメチル)−8−フェニル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2,3−ジクロロフェニル)(3−メチル−8−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−メチル−8−(ピリジン−2−イル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−クロロ−3−(トリフルオロメチル)フェニル)(8−(4−フルオロフェニル)−3−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−3−(トリフルオロメチル)フェニル)(8−(4−フルオロフェニル)−3−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(8−(4−フルオロフェニル)−3−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)(2−メチル−3−(トリフルオロメチル)フェニル)メタノン;
(S)−(8−(4−フルオロフェニル)−3−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)(2−メチル−3−(トリフルオロメチル)フェニル)メタノン;
(R)−(2−クロロ−4−フルオロフェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−クロロ−4−フルオロフェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2,4−ジクロロフェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,4−ジクロロフェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−メチル−3−(トリフルオロメチル)フェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−メチル−3−(トリフルオロメチル)フェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2,3−ジクロロ−4−フルオロフェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロ−4−フルオロフェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(±)−(8−(1H−ピラゾール−5−イル)−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)(2−クロロ−3−(トリフルオロメチル)フェニル)メタノン;
(±)−(2−クロロ−3−(トリフルオロメチル)フェニル)(8−(ピリジン−3−イル)−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(R)−(2−フルオロ−3−(トリフルオロメチル)フェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2−フルオロ−3−(トリフルオロメチル)フェニル)(8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(±)−(2−クロロ−3−(トリフルオロメチル)フェニル)(6−メチル−8−フェニル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(±)−ベンジル−3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)(2−クロロ−3−(トリフルオロメチル)フェニル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(4−ヒドロキシピリジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン;
(S)−(2,3−ジクロロフェニル)(3−(4−[11C]メトキシピリジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン及び
(S)−(2,3−ジクロロフェニル)(3−(4−[18F]フルオロピリジン−2−イル)−6−メチル−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)メタノン。 - (a)式(I)の化合物:
並びにその製薬学的に許容可能な塩から独立して選択される、治療的有効量の少なくとも1つの化合物
(式中、
Raは、
R1は、ハロ又はC1〜C3アルキルであり、
R2は、H、ハロ及びC1〜C3ペルハロアルキルからなる群から独立して選択され、
R3は、H又はハロであり、
R4は、ハロであり、
R5は、ハロ又はC1〜C3ペルハロアルキルであり、
Rbは、以下からなる群から独立して選択され、
R6、R9、R10、R12、R14は、独立して、H又はハロであり、
R7及びR13は、H、ハロ及びOC1〜C3アルキルからなる群から独立して選択され、
R8は、H、ハロ、OH及びOC1〜C3アルキルからなる群から独立して選択され、
R11は、H、ハロ及びC1〜C3ペルハロアルキルからなる群から独立して選択され、
Rcは、以下からなる群から選択され、
ただし、Rc、Rd及びReのうちの少なくとも1つは、Hではない。)と、
(b)少なくとも1つの製薬学的に許容可能な賦形剤と、を含む、医薬組成物。 - 治療的有効量の請求項44に記載の少なくとも1つの化合物と、少なくとも1つの製薬学的に許容可能な賦形剤と、を含む、医薬組成物。
- P2X7受容体活性によって媒介される疾患、障害、又は医学的状態を患うか又は該疾患、該障害、又は該医学的状態を有すると診断された対象を治療する方法であって、かかる治療を必要とする対象に、式(I)の化合物:
並びにその製薬学的に許容可能な塩から選択される、有効量の少なくとも1つの化合物
(式中、
Raは、
R1は、ハロ又はC1〜C3アルキルであり、
R2は、H、ハロ及びC1〜C3ペルハロアルキルからなる群から独立して選択され、
R3は、H又はハロであり、
R4は、ハロであり、
R5は、ハロ又はC1〜C3ペルハロアルキルであり、
Rbは、以下からなる群から独立して選択され、
R6、R9、R10、R12、R14は、独立して、H又はハロであり、
R7及びR13は、H、ハロ及びOC1〜C3アルキルからなる群から独立して選択され、
R8は、H、ハロ、OH及びOC1〜C3アルキルからなる群から独立して選択され、
R11は、H、ハロ及びC1〜C3ペルハロアルキルからなる群から独立して選択され、
Rcは、以下からなる群から選択され、
ただし、Rc、Rd及びReのうちの少なくとも1つは、Hではない。)を投与することを含む、方法。 - 前記疾患、障害又は医学的状態が、自己免疫・炎症系疾患;神経・神経免疫系疾患;中枢神経系(CNS)の神経炎症を伴う疾患及び伴わない疾患;心血管系、代謝系、胃腸系及び泌尿生殖系の疾患;骨格疾患、外分泌腺の分泌機能に関する疾患及び緑内障、糸球体腎炎、シャーガス病、クラミジア、神経芽細胞腫、結核、多発性嚢胞腎疾患、がん並びに座瘡からなる群から選択される、請求項47に記載の方法。
- 前記疾患、障害又は医学的状態が、関節リウマチ、変形性関節症、間質性膀胱炎、乾癬、敗血性ショック、敗血症、アレルギー性皮膚炎、喘息、アレルギー性喘息、軽度から重度の喘息及びステロイド抵抗性喘息、特発性肺線維症、アレルギー性鼻炎、慢性閉塞性肺疾患及び気道過敏性;急性及び慢性の疼痛、神経障害性疼痛、炎症性疼痛、片頭痛、自発痛、オピオイド誘発性疼痛、糖尿病性神経障害、帯状疱疹後神経痛、腰痛症、化学療法誘発性神経障害性疼痛、線維筋痛;気分障害、大うつ病、大うつ病性障害、治療抵抗性うつ病、双極性障害、不安うつ病、不安、認知、睡眠障害、多発性硬化症、てんかん発作、パーキンソン病、統合失調症、アルツハイマー病、ハンチントン病、筋萎縮性側索硬化症、自閉症、脊髄損傷及び脳虚血/外傷性脳損傷並びにストレス関連疾患;糖尿病、真性糖尿病、血栓症、過敏性腸疾患、過敏性腸症候群、クローン病、心臓血管疾患(心臓血管疾患の例には、高血圧、心筋梗塞、虚血性心疾患、虚血が挙げられる。)、尿管閉塞、下部尿路症候群、失禁などの下部尿路機能障害及び心臓移植後の疾患、骨粗鬆症/大理石骨病、外分泌腺の分泌機能に関する疾患、緑内障、糸球体腎炎、シャーガス病、クラミジア、神経芽細胞腫、結核、多発性嚢胞腎疾患、がん並びに座瘡からなる群から選択される、請求項47に記載の方法。
- 前記疾患、障害又は医学的状態が自己免疫・炎症系疾患である、請求項48に記載の方法。
- 前記自己免疫・炎症系疾患が、関節リウマチ、変形性関節症、間質性膀胱炎、乾癬、敗血性ショック、敗血症、アレルギー性皮膚炎、喘息、特発性肺線維症、アレルギー性鼻炎、慢性閉塞性肺疾患及び気道過敏性からなる群から選択される、請求項50に記載の方法。
- 前記疾患、障害又は医学的状態が中枢神経系(CNS)の神経炎症を伴う疾患及び伴わない疾患である、請求項48に記載の方法。
- 前記中枢神経系(CNS)の神経炎症を伴う疾患及び伴わない疾患が、気分障害、認知、睡眠障害、多発性硬化症、てんかん発作、パーキンソン病、統合失調症、アルツハイマー病、ハンチントン病、筋萎縮性側索硬化症、自閉症、脊髄損傷及び脳虚血/外傷性脳損傷並びにストレス関連疾患からなる群から選択される、請求項52に記載の方法。
- 前記気分障害が、大うつ病、大うつ病性障害、治療抵抗性うつ病、双極性障害、不安うつ病及び不安からなる群から選択される、請求項53に記載の方法。
- 前記気分障害が治療抵抗性うつ病である、請求項54に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462049727P | 2014-09-12 | 2014-09-12 | |
US62/049,727 | 2014-09-12 | ||
PCT/US2015/046852 WO2016039983A1 (en) | 2014-09-12 | 2015-08-26 | P2x7 modulating n-acyl-triazolopyrazines |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017527588A true JP2017527588A (ja) | 2017-09-21 |
JP6625616B2 JP6625616B2 (ja) | 2019-12-25 |
Family
ID=54062820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017513686A Active JP6625616B2 (ja) | 2014-09-12 | 2015-08-26 | P2x7調節n−アシル−トリアゾロピラジン |
Country Status (8)
Country | Link |
---|---|
US (2) | US20180118749A1 (ja) |
EP (1) | EP3191488B1 (ja) |
JP (1) | JP6625616B2 (ja) |
AU (1) | AU2015315693B2 (ja) |
CA (1) | CA2960972C (ja) |
EA (1) | EA201790600A1 (ja) |
IL (1) | IL251091A0 (ja) |
WO (1) | WO2016039983A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014152537A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | P2x7調控劑 |
EP3112366B1 (en) | 2013-03-14 | 2018-02-28 | Janssen Pharmaceutica NV | P2x7 modulators |
TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | P2x7調節劑 |
EA034015B1 (ru) | 2014-09-12 | 2019-12-19 | Янссен Фармацевтика Нв | Модуляторы р2х7 |
PL3287443T3 (pl) | 2015-04-24 | 2022-02-21 | Shionogi & Co., Ltd | 6-członowa pochodna heterocykliczna i kompozycja farmaceutyczna ją zawierająca |
MX2019004107A (es) * | 2016-10-17 | 2019-08-05 | Shionogi & Co | Derivado heterociclico nitrogenado biciclico y composicion farmaceutica que lo contiene. |
EP3609868B1 (en) | 2017-03-13 | 2023-10-18 | RaQualia Pharma Inc. | Tetrahydroquinoline derivatives as p2x7 receptor antagonists |
PE20211773A1 (es) | 2018-09-28 | 2021-09-08 | Janssen Pharmaceutica Nv | Moduladores de monoacilglicerol lipasa |
EP3856179A1 (en) | 2018-09-28 | 2021-08-04 | Janssen Pharmaceutica N.V. | Monoacylglycerol lipase modulators |
AU2020358948A1 (en) | 2019-09-30 | 2022-05-26 | Janssen Pharmaceutica Nv | Radiolabelled MGL PET ligands |
BR112022019077A2 (pt) | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012525352A (ja) * | 2009-04-29 | 2012-10-22 | グラクソ グループ リミテッド | P2X7調節因子としての5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[4,3−a]ピラジン誘導体 |
JP2012525351A (ja) * | 2009-04-30 | 2012-10-22 | グラクソ グループ リミテッド | P2X7調節因子としての5,6,7,8−テトラヒドロイミダゾ[1,2−a]ピラジン誘導体 |
JP2013523697A (ja) * | 2010-04-02 | 2013-06-17 | ユーロスクリーン エス.エー. | 新規のnk−3受容体選択的アンタゴニスト化合物、医薬組成物、及びnk−3受容体媒介疾患における使用方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2989103B1 (en) * | 2013-03-29 | 2019-02-20 | Ogeda Sa | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
-
2015
- 2015-08-26 WO PCT/US2015/046852 patent/WO2016039983A1/en active Application Filing
- 2015-08-26 JP JP2017513686A patent/JP6625616B2/ja active Active
- 2015-08-26 CA CA2960972A patent/CA2960972C/en active Active
- 2015-08-26 EA EA201790600A patent/EA201790600A1/ru unknown
- 2015-08-26 AU AU2015315693A patent/AU2015315693B2/en active Active
- 2015-08-26 US US15/541,040 patent/US20180118749A1/en not_active Abandoned
- 2015-08-26 EP EP15759592.7A patent/EP3191488B1/en active Active
-
2017
- 2017-03-12 IL IL251091A patent/IL251091A0/en unknown
-
2022
- 2022-02-07 US US17/650,155 patent/US20220235062A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012525352A (ja) * | 2009-04-29 | 2012-10-22 | グラクソ グループ リミテッド | P2X7調節因子としての5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[4,3−a]ピラジン誘導体 |
JP2012525351A (ja) * | 2009-04-30 | 2012-10-22 | グラクソ グループ リミテッド | P2X7調節因子としての5,6,7,8−テトラヒドロイミダゾ[1,2−a]ピラジン誘導体 |
JP2013523697A (ja) * | 2010-04-02 | 2013-06-17 | ユーロスクリーン エス.エー. | 新規のnk−3受容体選択的アンタゴニスト化合物、医薬組成物、及びnk−3受容体媒介疾患における使用方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3191488B1 (en) | 2019-08-14 |
JP6625616B2 (ja) | 2019-12-25 |
EA201790600A1 (ru) | 2017-07-31 |
AU2015315693A1 (en) | 2017-03-30 |
EP3191488A1 (en) | 2017-07-19 |
US20180118749A1 (en) | 2018-05-03 |
IL251091A0 (en) | 2017-04-30 |
US20220235062A1 (en) | 2022-07-28 |
CA2960972A1 (en) | 2016-03-17 |
CA2960972C (en) | 2023-10-03 |
AU2015315693B2 (en) | 2020-01-16 |
WO2016039983A1 (en) | 2016-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6625616B2 (ja) | P2x7調節n−アシル−トリアゾロピラジン | |
JP6294954B2 (ja) | P2x7調節物質 | |
JP6115962B2 (ja) | 1−アリール−4−メチル−[1,2,4]トリアゾロ[4,3−a]キノキサリン誘導体 | |
KR102500076B1 (ko) | P2x7 조절제 | |
JP6294953B2 (ja) | P2x7調節物質 | |
JP4709849B2 (ja) | アルツハイマー病治療のためのグリシントランスポーターi(glyt−1)インヒビターとしての二環式及び三環式置換フェニルメタノン類 | |
RU2677696C1 (ru) | Производные бензотриазола в качестве модуляторов активности tnf | |
JP6592510B2 (ja) | P2x7調節因子 | |
US10513523B2 (en) | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators | |
JP7073385B2 (ja) | タンパク質凝集のモジュレーターとしての二環式ビス-ヘテロアリール誘導体 | |
JP6467404B2 (ja) | P2x7モジュレーター | |
KR20230026405A (ko) | Nav1.8 억제제로서의 5-옥소피롤리딘-3-카르복스아미드 | |
US11142526B2 (en) | Spirocycle compounds and methods of making and using same | |
WO2015027431A1 (en) | 2,2-difluorodioxolo a2a receptor antagonists | |
JP2020524148A (ja) | 置換5−シアノインドール化合物及びその使用 | |
ES2782088T3 (es) | Compuestos novedosos | |
EP2757883B1 (en) | Triazolopyridyl compounds as aldosterone synthase inhibitors | |
KR102611539B1 (ko) | Gsk-3 억제제 | |
JP2021530474A (ja) | 7−アミノ−5−チオ−チアゾロ[4,5−d]ピリミジンのリン酸塩およびホスホン酸塩誘導体ならびにcx3cr1および/またはcx3cl1のレベルの上昇に関連する治療条件におけるそれらの使用 | |
KR20190097258A (ko) | Pde2 억제제로서 치환된 피라졸로피리미디논 화합물 | |
US20230203032A1 (en) | Naphthyridinone derivatives for the treatment of a disease or disorder | |
CN115784986A (zh) | 一种hdac6抑制剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180817 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190516 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190521 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191021 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191127 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6625616 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |